{
  "validation_metadata": {
    "timestamp": "20250908_200000",
    "test_model": "deepseek-coder",
    "prompts_tested": [
      "direct_mcode_simple",
      "direct_mcode_evidence_based_concise"
    ],
    "trials_count": 5,
    "validation_version": "1.0"
  },
  "results": {
    "direct_mcode_simple": {
      "prompt_name": "direct_mcode_simple",
      "model_name": "deepseek-coder",
      "trials_processed": 5,
      "total_processing_time": 644.7767910957336,
      "trial_results": [
        {
          "trial_id": "NCT01922921",
          "processing_time": 0.04343104362487793,
          "mcode_mappings": [
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "interventional",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"primaryPurpose\": \"TREATMENT\"",
              "mapping_rationale": "TREATMENT purpose indicates an interventional study type per FHIR ResearchStudy",
              "id": "aa770c17-00e1-4113-b6bb-00ccf991d537"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "RANDOMIZED",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"allocation\": \"RANDOMIZED\"",
              "mapping_rationale": "RANDOMIZED allocation directly maps to FHIR ResearchStudy design",
              "id": "967e3bde-e715-4e96-ad34-948f3eaf8275"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "PARALLEL",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"interventionModel\": \"PARALLEL\"",
              "mapping_rationale": "PARALLEL intervention model directly maps to FHIR ResearchStudy design",
              "id": "09065c42-c758-42ec-af32-e6eeb602bb10"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "DOUBLE",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"masking\": \"DOUBLE\"",
              "mapping_rationale": "DOUBLE masking directly maps to FHIR ResearchStudy masking type",
              "id": "547dff7b-8c66-4a17-a841-b8f286876fdc"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "PARTICIPANT",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"PARTICIPANT\"",
              "mapping_rationale": "PARTICIPANT role directly maps to FHIR ResearchStudy masked roles",
              "id": "3ed4953d-930d-400f-a37b-a23383fa093b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "INVESTIGATOR",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"INVESTIGATOR\"",
              "mapping_rationale": "INVESTIGATOR role directly maps to FHIR ResearchStudy masked roles",
              "id": "1492d3cb-eca1-41e7-bb5d-aae39344acfb"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "active",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Recurrent Breast Carcinoma",
              "mapping_rationale": "Mapped to SNOMED CT code for malignant breast neoplasm, with 'recurrent' indicating active disease status",
              "id": "3e117832-d5ef-4558-bf7f-5f26b0f93a95"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "active",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Stage IV Breast Cancer",
              "mapping_rationale": "Mapped to SNOMED CT code for malignant breast neoplasm, with stage IV indicating advanced active disease",
              "id": "526fff2c-b20e-4f3a-9f3c-59427f871e38"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "recurrence",
              "mapping_confidence": 0.85,
              "source_text_fragment": "Recurrent Breast Carcinoma",
              "mapping_rationale": "'Recurrent' indicates disease recurrence status per mCODE value set",
              "id": "976f1192-1d12-40cf-9b42-1024a4843d8d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStageGroup",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstagegroup",
                "display": "TNMStageGroup"
              },
              "value": "IV",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Stage IV Breast Cancer",
              "mapping_rationale": "Direct mapping of 'Stage IV' to TNM stage group using cancer staging terminology",
              "id": "0c97fa96-fab4-4a37-a7e6-b949d4cab574"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "positive",
              "mapping_confidence": 0.8,
              "source_text_fragment": "HER2/Neu Positive",
              "mapping_rationale": "HER2/Neu maps to ERBB2 gene (HGNC:3430), 'Positive' indicates variant presence",
              "id": "a8d8df14-6070-4fbb-9712-8cc34528fe58"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "stage IV HER2+ breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Patients with stage IV HER2+ breast cancer",
              "mapping_rationale": "Direct mapping to cancer condition with stage and HER2 status specified",
              "id": "10f44904-a034-472f-8bb4-4d9023853154"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "No evidence of disease (NED)",
              "mapping_confidence": 1.0,
              "source_text_fragment": "No evidence of disease (NED)",
              "mapping_rationale": "Clear disease status observation from inclusion criteria",
              "id": "a9f2d077-670b-4682-b5f6-e609f1df85fa"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "Stable bone only disease",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stable bone only disease after definitive therapy",
              "mapping_rationale": "Clear disease status observation with metastatic site specified",
              "id": "dc80d667-943f-4a8e-8dce-352c0484a24e"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in the primary tumor or metastasis",
              "mapping_rationale": "HER2 genomic variant testing results with specific IHC scores",
              "id": "d222dddc-f316-41cb-878a-0caea9c812dc"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "HER2 gene amplification documented by FISH analysis",
              "mapping_confidence": 1.0,
              "source_text_fragment": "documented gene amplification by fluorescent in situ hybridization (FISH) analysis",
              "mapping_rationale": "HER2 genomic variant testing using FISH methodology",
              "id": "c21cb08d-6e8f-4da8-9dbb-be2c595d7619"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "trastuzumab monotherapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "trastuzumab monotherapy",
              "mapping_rationale": "HER2-targeted monoclonal antibody therapy specified in treatment criteria",
              "id": "4bb11b33-e3be-413f-861c-d0fb232d6157"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "trastuzumab and pertuzumab combination therapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "trastuzumab and pertuzumab combination therapy",
              "mapping_rationale": "HER2-targeted combination therapy specified in treatment criteria",
              "id": "9dae2ca4-af61-40e7-8ada-206c72090d14"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ECOGPerformanceStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "ecogperformancestatus",
                "display": "ECOGPerformanceStatus"
              },
              "value": "Zubrod performance status score of =< 2",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Patients must have Zubrod performance status score of =< 2",
              "mapping_rationale": "Performance status assessment using Zubrod/ECOG scale with score threshold",
              "id": "1ef11d24-9bab-4e3b-aff8-3cf9acd85223"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "LaboratoryResult",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "laboratoryresult",
                "display": "LaboratoryResult"
              },
              "value": "White blood cell (WBC) >= 3000/mm^3",
              "mapping_confidence": 1.0,
              "source_text_fragment": "White blood cell (WBC) >= 3000/mm^3",
              "mapping_rationale": "Laboratory result threshold for white blood cell count",
              "id": "c61b1b04-01c0-47ec-970b-7e52f91ab161"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "LaboratoryResult",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "laboratoryresult",
                "display": "LaboratoryResult"
              },
              "value": "Hemoglobin (Hgb) >= 10 g/dl",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Hemoglobin (Hgb) >= 10 g/dl",
              "mapping_rationale": "Laboratory result threshold for hemoglobin level",
              "id": "135570e7-a961-484f-bbe8-7518e1030696"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "LaboratoryResult",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "laboratoryresult",
                "display": "LaboratoryResult"
              },
              "value": "Serum creatinine =< 2.0 mg/dl",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Serum creatinine =< 2.0 mg/dl",
              "mapping_rationale": "Laboratory result threshold for serum creatinine",
              "id": "4a6fdf94-b7eb-435d-a381-791656776d1e"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "LaboratoryResult",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "laboratoryresult",
                "display": "LaboratoryResult"
              },
              "value": "Total bilirubin =< 1.5 mg/dl",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Total bilirubin =< 1.5 mg/dl",
              "mapping_rationale": "Laboratory result threshold for total bilirubin",
              "id": "a92d0704-c379-431b-925e-86c33d49862c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "LaboratoryResult",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "laboratoryresult",
                "display": "LaboratoryResult"
              },
              "value": "SGOT =< 2.5 times the upper limit of normal",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 times the upper limit of normal",
              "mapping_rationale": "Laboratory result threshold for SGOT/AST liver enzyme",
              "id": "80166697-4a30-4c1c-925e-7b148c072859"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CardiacFunction",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cardiacfunction",
                "display": "CardiacFunction"
              },
              "value": "normal left ventricular ejection fraction (LVEF) >= the lower limit of normal",
              "mapping_confidence": 1.0,
              "source_text_fragment": "normal left ventricular ejection fraction (LVEF) >= the lower limit of normal for the facility on multi gated acquisition (MUGA) scan or echocardiogram (ECHO) within 3 months of enrollment",
              "mapping_rationale": "Cardiac function assessment with LVEF measurement and normal range specification",
              "id": "e64b02a3-2b13-4978-9246-de0d6dd744f3"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "Restrictive cardiomyopathy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Restrictive cardiomyopathy",
              "mapping_rationale": "Cardiac comorbidity listed in exclusion criteria",
              "id": "6183c3e5-ee36-46e2-8f3c-987ca0144d96"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "Unstable angina within 6 months prior to enrollment",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Unstable angina within 6 months prior to enrollment",
              "mapping_rationale": "Cardiac comorbidity with temporal constraint in exclusion criteria",
              "id": "483300b2-1d86-407e-95ef-0af7958b57f7"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "New York Heart Association functional class III-IV heart failure",
              "mapping_confidence": 1.0,
              "source_text_fragment": "New York Heart Association functional class III-IV heart failure",
              "mapping_rationale": "Cardiac comorbidity with severity classification in exclusion criteria",
              "id": "c694d164-106f-45ee-87c5-b199c2967a8c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "Symptomatic pericardial effusion",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Symptomatic pericardial effusion",
              "mapping_rationale": "Cardiac comorbidity with symptom specification in exclusion criteria",
              "id": "6fdd9ea9-e083-49b8-9cd0-65765e4b4dad"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "minimumAge: 18 Years",
              "mapping_confidence": 1.0,
              "source_text_fragment": "minimumAge: 18 Years",
              "mapping_rationale": "Minimum age requirement for patient eligibility",
              "id": "c073952d-284d-4fa6-9866-d724cfb18678"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
              "mapping_confidence": 0.95,
              "source_text_fragment": "stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
              "mapping_rationale": "Text clearly describes cancer condition with stage and HER2 status",
              "id": "fddb42e9-e7cc-43de-bb5e-78019ee9e3f6"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "unknown",
              "mapping_confidence": 0.85,
              "source_text_fragment": "It is not yet known whether vaccine therapy works better when given with or without polysaccharide-K in treating breast cancer",
              "mapping_rationale": "Text indicates disease status/outcome is unknown for the treatment comparison",
              "id": "fa35662f-f6e8-4788-ba2c-892cf1acf159"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "trastuzumab",
              "mapping_confidence": 0.98,
              "source_text_fragment": "trastuzumab (or trastuzumab and pertuzumab) per standard of care",
              "mapping_rationale": "Trastuzumab is explicitly mentioned as HER2-targeted therapy",
              "id": "0791d979-1ab9-420d-81c4-328ebd46feba"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "pertuzumab",
              "mapping_confidence": 0.9,
              "source_text_fragment": "trastuzumab and pertuzumab",
              "mapping_rationale": "Pertuzumab is mentioned as alternative or combination therapy",
              "id": "bde70f17-4349-4eba-918e-1c9dc2eb91ce"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "polysaccharide-K",
              "mapping_confidence": 0.8,
              "source_text_fragment": "polysaccharide-K PO BID for 4 months",
              "mapping_rationale": "Polysaccharide-K is an investigational medication in the trial",
              "id": "ef180fb3-7ea9-4384-ad7d-80343147fdbe"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "vaccine therapy",
              "mapping_confidence": 0.88,
              "source_text_fragment": "vaccine therapy with or without polysaccharide-K",
              "mapping_rationale": "Vaccine therapy is a form of cancer immunotherapy procedure",
              "id": "3dd35b88-a603-47ef-a574-e6f040141d8b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "positive",
              "mapping_confidence": 0.92,
              "source_text_fragment": "HER2 positive breast cancer",
              "mapping_rationale": "HER2 positive status is a key tumor marker for patient selection",
              "id": "ad170b07-3732-4f85-9cae-48bc5176e5ea"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "natural killer (NK) cell functional activity",
              "mapping_confidence": 0.85,
              "source_text_fragment": "natural killer (NK) cell functional activity",
              "mapping_rationale": "NK cell activity is measured as a secondary objective biomarker",
              "id": "248eb5c8-f196-4720-bf67-54a86605d2c2"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "serum transforming growth factor (TGF)-beta levels",
              "mapping_confidence": 0.9,
              "source_text_fragment": "serum transforming growth factor (TGF)-beta levels",
              "mapping_rationale": "TGF-beta is measured as a tertiary objective biomarker",
              "id": "15e1f433-a93b-48fd-b845-39aabf0f63ca"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "progression free survival (PFS)",
              "mapping_confidence": 0.95,
              "source_text_fragment": "progression free survival (PFS)",
              "mapping_rationale": "PFS is explicitly mentioned as a tertiary outcome measure",
              "id": "f09cc5cc-23dd-4cea-ada1-8a98352c2a83"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "overall survival (OS)",
              "mapping_confidence": 0.95,
              "source_text_fragment": "overall survival (OS)",
              "mapping_rationale": "OS is explicitly mentioned as a tertiary outcome measure",
              "id": "e73b9049-3ccd-4b90-80f4-5d67f7987f1b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "RadiationProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "radiationprocedure",
                "display": "RadiationProcedure"
              },
              "value": "phase I/II trial",
              "mapping_confidence": 0.7,
              "source_text_fragment": "randomized phase I/II trial",
              "mapping_rationale": "Clinical trial phase indicates radiation/oncology procedure context",
              "id": "957899e0-f78a-4d79-890b-b7165f8bafb6"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Stage IV HER2 Positive Breast Cancer",
              "mapping_rationale": "Text explicitly states breast cancer diagnosis with stage IV and HER2 positive status",
              "id": "e1180304-7a2a-41d1-b4f0-6a1b8808aeb2"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "IV",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Stage IV",
              "mapping_rationale": "Clear staging information provided as Stage IV breast cancer",
              "id": "536e2b7d-d4b9-4407-b954-61d759be4a29"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "positive",
              "mapping_confidence": 0.9,
              "source_text_fragment": "HER2 Positive",
              "mapping_rationale": "HER2 positive status explicitly stated, indicating genomic variant status",
              "id": "6002b992-a480-4234-a233-d3e86aaf0330"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "administered",
              "mapping_confidence": 0.85,
              "source_text_fragment": "HER2-targeted monoclonal antibody therapy",
              "mapping_rationale": "HER2-targeted therapy mentioned as current treatment regimen",
              "id": "171813fa-5fd4-40a3-8c11-71d5f5c719f7"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "planned",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Vaccine Therapy",
              "mapping_rationale": "Vaccine therapy mentioned as part of the treatment approach",
              "id": "a0bd23b1-53cc-4e35-8032-022b52b69848"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "under investigation",
              "mapping_confidence": 0.75,
              "source_text_fragment": "Polysaccharide-K",
              "mapping_rationale": "Polysaccharide-K mentioned as investigational therapy component",
              "id": "91e049da-46f3-49af-ad78-9c75c30c2557"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "HER2 positive",
              "mapping_confidence": 0.9,
              "source_text_fragment": "HER2 Positive Breast Cancer",
              "mapping_rationale": "HER2 status is a key genomic variant inclusion criterion for the study",
              "id": "3ac0b567-429c-4c0b-85e6-0df2a5aeeb50"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "stage IV",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Stage IV Breast Cancer",
              "mapping_rationale": "Study specifically targets patients with stage IV breast cancer",
              "id": "3d92cb7b-4c1b-49fd-ae74-f79bda283f2c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "HER2 ICD peptide-based vaccine clinical trial",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.",
              "mapping_rationale": "Clinical trial description with treatment arms and interventions",
              "id": "e3f64340-eb15-4a9d-b0b8-8c30bb5bd061"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "administered per standard of care",
              "mapping_confidence": 1.0,
              "source_text_fragment": "trastuzumab (or trastuzumab and pertuzumab) per standard of care",
              "mapping_rationale": "HER2-targeted therapy medication mentioned in treatment protocol",
              "id": "807e5efe-cf9c-4373-a8de-86643591a864"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "administered per standard of care",
              "mapping_confidence": 1.0,
              "source_text_fragment": "pertuzumab: Given per standard of care",
              "mapping_rationale": "HER2-targeted therapy medication explicitly listed",
              "id": "d4bb1fb9-9759-4b12-a5da-176177e3f219"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "positive",
              "mapping_confidence": 0.8,
              "source_text_fragment": "HER2 ICD peptide-based vaccine",
              "mapping_rationale": "HER2-targeted vaccine implies HER2-positive cancer status",
              "id": "d4d36bb7-2267-4eaf-92a0-e33d94442015"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "positive",
              "mapping_confidence": 0.8,
              "source_text_fragment": "HER2 ICD peptide-based vaccine",
              "mapping_rationale": "HER2-targeted therapy indicates HER2 biomarker positivity",
              "id": "0d83c37e-aef0-4e78-9bca-8b5c9ab257da"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMClinicalStageGroup",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmclinicalstagegroup",
                "display": "TNMClinicalStageGroup"
              },
              "value": "metastatic or advanced (inferred)",
              "mapping_confidence": 0.6,
              "source_text_fragment": "trastuzumab (or trastuzumab and pertuzumab) per standard of care",
              "mapping_rationale": "Dual HER2 blockade typically used in metastatic setting",
              "id": "fb813118-c7f8-4eab-b2fa-54b6bd7286bb"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchSubject",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchsubject",
                "display": "ResearchSubject"
              },
              "value": "clinical trial participant",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Patients receive HER2 ICD peptide-based vaccine",
              "mapping_rationale": "Clinical trial participants described in treatment arms",
              "id": "50918262-c0e1-4b36-96dc-5e1c2999ed5d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "correlative studies",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Laboratory Biomarker Analysis: Correlative studies",
              "mapping_rationale": "Explicit mention of laboratory biomarker analysis",
              "id": "d0765937-efc9-4b2f-8ca4-80ce7a323abf"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PerformanceStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "performancestatus",
                "display": "PerformanceStatus"
              },
              "value": "adequate for clinical trial (inferred)",
              "mapping_confidence": 0.5,
              "source_text_fragment": "Patients receive HER2 ICD peptide-based vaccine",
              "mapping_rationale": "Clinical trial participation implies adequate performance status",
              "id": "8e1393da-defa-4f1c-abd4-a9fe3bf0fdaa"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "intradermal administration",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER-2/neu Intracellular Domain Protein: Given ID",
              "mapping_rationale": "Vaccine administration method specified as intradermal",
              "id": "130b5ec9-ecf3-4f5b-827f-87945ad81ea8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Toxicity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "toxicity",
                "display": "Toxicity"
              },
              "value": "Grade 3 or higher",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Number of Patients With Grade 3 or Higher Toxicity Per Study Arm.",
              "mapping_rationale": "Direct mapping to toxicity grading using CTCAE v4.0 terminology",
              "id": "9fdc68d9-c2a0-48a3-b8f6-9b88186f0db4"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Toxicity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "toxicity",
                "display": "Toxicity"
              },
              "value": "Present",
              "mapping_confidence": 0.8,
              "source_text_fragment": "possibly related event of vomiting",
              "mapping_rationale": "Specific toxicity event mentioned in population description",
              "id": "892284b3-a4d9-4e36-b422-b6a403baf652"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Quantitative",
              "mapping_confidence": 0.85,
              "source_text_fragment": "CD56dim CD16bright NK cells",
              "mapping_rationale": "Flow cytometry analysis of NK cell markers CD56 and CD16",
              "id": "f69192d3-ca39-49a5-85e6-464633da78b0"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Quantitative",
              "mapping_confidence": 0.85,
              "source_text_fragment": "CD56bright CD16dim",
              "mapping_rationale": "Flow cytometry analysis of NK cell markers CD56 and CD16",
              "id": "185f8a89-c74a-4de6-a5db-1b04bfd65e8c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Quantitative",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Interferon (IFN)-Gamma Production",
              "mapping_rationale": "Direct measurement of IFN-gamma production in NK cells",
              "id": "0cd6ef38-b049-4295-aeab-a80d7b360f61"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Quantitative",
              "mapping_confidence": 0.9,
              "source_text_fragment": "CD107a Expression in NK Cells",
              "mapping_rationale": "Direct measurement of CD107a expression as marker of NK cell activity",
              "id": "d7371fa0-d1c9-4e79-b67a-dd338c64291d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Quantitative",
              "mapping_confidence": 0.8,
              "source_text_fragment": "IFN-gamma Enzyme-linked Immunosorbent Spot Assay",
              "mapping_rationale": "ELISPOT assay for IFN-gamma to assess T cell response",
              "id": "58af635f-7fa6-4dc1-b9ad-0197fdbec805"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Quantitative",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Serum TGF-beta Levels Assessed by Enzyme-linked Immunosorbent Assay",
              "mapping_rationale": "ELISA measurement of TGF-beta levels as cancer biomarker",
              "id": "96f3b691-52ad-4b56-8f5e-e93fe08f4f57"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "Measured",
              "mapping_confidence": 0.7,
              "source_text_fragment": "OS",
              "mapping_rationale": "Overall survival as key oncology outcome measure",
              "id": "21bb46e6-03c4-400e-a926-4dda2801c891"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "Measured",
              "mapping_confidence": 0.7,
              "source_text_fragment": "PFS",
              "mapping_rationale": "Progression-free survival as key oncology outcome measure",
              "id": "2bad075b-ea71-4f24-bab4-90abc5d1b04e"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 70,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 2976,
              "completion_tokens": 1321,
              "total_tokens": 4297
            },
            "aggregate_token_usage": {
              "prompt_tokens": 0,
              "completion_tokens": 0,
              "total_tokens": 0,
              "model_name": "",
              "provider_name": ""
            }
          }
        },
        {
          "trial_id": "NCT01026116",
          "processing_time": 0.012052059173583984,
          "mcode_mappings": [
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "interventional",
              "mapping_confidence": 0.9,
              "source_text_fragment": "\"primaryPurpose\": \"TREATMENT\"",
              "mapping_rationale": "TREATMENT purpose indicates an interventional study type per mCODE ResearchStudy profile",
              "id": "b6add2d9-91d4-42cb-bd2f-260188a1e25d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "randomized",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"allocation\": \"RANDOMIZED\"",
              "mapping_rationale": "Direct mapping of RANDOMIZED to FHIR randomized allocation type",
              "id": "a0548afa-2d98-46f5-8aac-a956912fc8ce"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "parallel",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"interventionModel\": \"PARALLEL\"",
              "mapping_rationale": "Direct mapping of PARALLEL to FHIR parallel study design",
              "id": "878d5c81-bda9-49c0-80c8-e5bd3d8da810"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "none",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"masking\": \"NONE\"",
              "mapping_rationale": "Direct mapping of NONE to FHIR no masking type",
              "id": "1a66d76b-d931-49a8-adae-105b6170c89d"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "active",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Breast Neoplasms",
              "mapping_rationale": "The term 'Breast Neoplasms' maps to SNOMED CT code 254837009 for malignant neoplasm of breast, which is a primary cancer condition in mCODE",
              "id": "5307ca77-c36e-4ec3-9108-4d74a055f430"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 1.0,
              "source_text_fragment": "histologically confirmed adenocarcinoma of the breast",
              "mapping_rationale": "Text confirms breast cancer diagnosis with histological verification",
              "id": "4d2f0817-cd83-41f4-a572-f73daf3a89d9"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Stage I-III",
              "mapping_rationale": "Cancer stage range includes stage I, mapped to SNOMED CT code for stage I breast cancer",
              "id": "7a912614-0f9c-48d2-9fe5-d016b38488d5"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Stage I-III",
              "mapping_rationale": "Cancer stage range includes stage II, mapped to SNOMED CT code for stage II breast cancer",
              "id": "fba76a2d-3516-4af4-b8d4-1cafc0be832f"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Stage I-III",
              "mapping_rationale": "Cancer stage range includes stage III, mapped to SNOMED CT code for stage III breast cancer",
              "id": "dabdb095-cf06-411e-887f-36b108269b69"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "performed",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Primary surgery with clear margins plus axillary dissection",
              "mapping_rationale": "Describes surgical procedure for breast cancer treatment including margin clearance and axillary dissection",
              "id": "d8bb1e40-326c-40ca-852a-705d29ff3603"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ERStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "erstatus",
                "display": "ERStatus"
              },
              "value": "positive",
              "mapping_confidence": 1.0,
              "source_text_fragment": "estrogen-receptor positive (ER+) breast cancer: the immunohistochemical cut-off for ER positive status was 1% or more staining in nuclei",
              "mapping_rationale": "Explicitly states ER positive status with specific immunohistochemical criteria",
              "id": "10f6f1e4-6452-4ba4-924e-18eb6c37728a"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "HER2Status",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "her2status",
                "display": "HER2Status"
              },
              "value": "negative",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test",
              "mapping_rationale": "Explicitly states HER2 negative status with specific test criteria",
              "id": "70ed12cd-8051-4b44-9abb-7d0c3c97f5d9"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "RegionalNodesPositive",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "regionalnodespositive",
                "display": "RegionalNodesPositive"
              },
              "value": "present",
              "mapping_confidence": 0.85,
              "source_text_fragment": "pathologically confirmed regional node-positive disease",
              "mapping_rationale": "Confirms presence of positive regional lymph nodes in breast cancer",
              "id": "993780ab-e3b5-489b-8c4d-7f44139aefa1"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ECOGPerformanceStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "ecogperformancestatus",
                "display": "ECOGPerformanceStatus"
              },
              "value": "0-1",
              "mapping_confidence": 1.0,
              "source_text_fragment": "ECOG performance status 0-1",
              "mapping_rationale": "Direct mapping of ECOG performance status score range",
              "id": "f1ee6e10-832b-42c0-981c-b42690a196c8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "female",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Female patients",
              "mapping_rationale": "Explicit gender specification for patient population",
              "id": "3d65ab08-5aa6-42e4-92b6-5c985e70d911"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "18-40",
              "mapping_confidence": 1.0,
              "source_text_fragment": "age 18~40",
              "mapping_rationale": "Age range specification for patient eligibility",
              "id": "5b11a90a-f93a-4464-aa5b-6b173487b71a"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "present",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Adequate cardiac function",
              "mapping_rationale": "Indicates absence of significant cardiac comorbidity through adequate function assessment",
              "id": "0fdc6523-6661-4677-a183-0eee1bf8db1a"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "present",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Adequate renal function",
              "mapping_rationale": "Indicates absence of significant renal comorbidity through adequate function assessment",
              "id": "bce6208a-f127-4d11-86e3-6d236d51438b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "present",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Adequate hepatic function",
              "mapping_rationale": "Indicates absence of significant hepatic comorbidity through adequate function assessment",
              "id": "6195c7ee-9baf-4838-a032-49c066ea80f9"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "absent",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Exclusion Criteria: Metastatic disease",
              "mapping_rationale": "Exclusion of metastatic disease implies absence of metastasis for included patients",
              "id": "cf9f2257-6bc0-4822-9e24-2ddc59457466"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "breast cancer patients",
              "mapping_rationale": "Text explicitly mentions breast cancer patients, indicating presence of cancer condition",
              "id": "170eb27c-b1fa-44ab-9070-00f0f997150c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "active",
              "mapping_confidence": 0.8,
              "source_text_fragment": "breast cancer patients",
              "mapping_rationale": "Reference to patients implies active disease status requiring treatment",
              "id": "2d7347cd-bfbd-4988-b1ee-dc6731c215ce"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "planned",
              "mapping_confidence": 0.9,
              "source_text_fragment": "paclitaxel",
              "mapping_rationale": "Paclitaxel is explicitly mentioned as part of the treatment strategy being evaluated",
              "id": "8f94b1f5-89d2-4f1e-aa09-f3a6508e01ae"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "planned",
              "mapping_confidence": 0.9,
              "source_text_fragment": "anthracycline-based regimens",
              "mapping_rationale": "Anthracycline-based regimens are mentioned as the foundation for treatment strategies",
              "id": "4fe61b08-4b7f-48a7-b971-bcec9e732c8d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "aggressive",
              "mapping_confidence": 0.85,
              "source_text_fragment": "aggressive clinical history",
              "mapping_rationale": "Text describes patients as having aggressive clinical history, which is a tumor marker characteristic",
              "id": "5986bb01-d987-47e0-8976-3af3bc2526b8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "young",
              "mapping_confidence": 0.7,
              "source_text_fragment": "young breast cancer patients",
              "mapping_rationale": "Text specifies 'young' patients, indicating age is a relevant demographic factor",
              "id": "66d1295a-68ae-4f88-aa91-9433b9d472cf"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "true",
              "mapping_confidence": 0.95,
              "source_text_fragment": "The purpose of this study is to evaluate",
              "mapping_rationale": "Text explicitly describes a research study purpose and objectives",
              "id": "7d716f5a-d5db-4ac9-9870-dea5a91fa681"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Breast Cancer",
              "mapping_rationale": "Text explicitly mentions 'Breast Cancer' which maps to SNOMED CT code for malignant neoplasm of breast",
              "id": "c76c665e-7c54-4a53-b03f-bee2c8d5d02d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "post-operative",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Operable Breast Cancer",
              "mapping_rationale": "'Operable' implies the cancer is in a state where surgery is possible, indicating post-operative status for adjuvant therapy",
              "id": "15531240-cb4c-4876-8123-0cdff59e6351"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "administered",
              "mapping_confidence": 0.85,
              "source_text_fragment": "EC-wP",
              "mapping_rationale": "'EC' in chemotherapy regimen typically refers to Epirubicin + Cyclophosphamide",
              "id": "c2a140cb-6a9c-49e0-a6a7-2d0aacf10416"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "administered",
              "mapping_confidence": 0.85,
              "source_text_fragment": "EC-wP",
              "mapping_rationale": "'EC' in chemotherapy regimen typically refers to Epirubicin + Cyclophosphamide",
              "id": "ee408d7a-083d-4b41-b2bb-9d675e16e01f"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "administered",
              "mapping_confidence": 0.8,
              "source_text_fragment": "wP",
              "mapping_rationale": "'wP' likely refers to weekly Paclitaxel regimen in adjuvant chemotherapy",
              "id": "ee17ddfa-eeea-4595-8e4c-de6a48f8ef08"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "administered",
              "mapping_confidence": 0.7,
              "source_text_fragment": "EP-wP",
              "mapping_rationale": "'EP' could refer to Epirubicin + Platinum agent (likely Cisplatin) in chemotherapy regimen",
              "id": "8f2df9bb-4966-4ec0-a95a-0e046932853a"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "performed",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Operable Breast Cancer",
              "mapping_rationale": "'Operable' implies surgical intervention is planned or has occurred for breast cancer treatment",
              "id": "9b3175f9-e79e-44e7-b0e3-b59aaa8700a6"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMClinicalStageGroup",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmclinicalstagegroup",
                "display": "TNMClinicalStageGroup"
              },
              "value": "unknown",
              "mapping_confidence": 0.6,
              "source_text_fragment": "Operable Breast Cancer",
              "mapping_rationale": "'Operable' suggests early stage cancer but specific TNM stage is not provided in text",
              "id": "232eaa54-de93-45d5-8c54-501bc120a947"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "not assessed",
              "mapping_confidence": 0.7,
              "source_text_fragment": "A Randomized Trial",
              "mapping_rationale": "Clinical trial context suggests genomic variants may be assessed but no specific variants mentioned in provided text",
              "id": "3ec66b5d-a854-4d74-8b5f-7434dba5b6da"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "age < 40 years",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Patients Less Than 40 Years Old",
              "mapping_rationale": "Text specifies patient population as breast cancer patients under 40 years old",
              "id": "8bcabf82-d44f-46b8-a842-8451be4fa4e5"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 37,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 558,
              "completion_tokens": 1312,
              "total_tokens": 1870
            },
            "aggregate_token_usage": {
              "prompt_tokens": 0,
              "completion_tokens": 0,
              "total_tokens": 0,
              "model_name": "",
              "provider_name": ""
            }
          }
        },
        {
          "trial_id": "NCT06650748",
          "processing_time": 196.79370784759521,
          "mcode_mappings": [
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "interventional",
              "mapping_confidence": 0.9,
              "source_text_fragment": "\"primaryPurpose\": \"TREATMENT\"",
              "mapping_rationale": "TREATMENT purpose indicates an interventional study type per mCODE ResearchStudy profile",
              "id": "f00b4a7f-372d-4b22-a241-69e2ccbccb27"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "randomized",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"allocation\": \"RANDOMIZED\"",
              "mapping_rationale": "Direct mapping of RANDOMIZED to FHIR randomized allocation type",
              "id": "bdbb275f-14d6-4fcd-9cd9-9b3879ca0228"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "parallel",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"interventionModel\": \"PARALLEL\"",
              "mapping_rationale": "Direct mapping of PARALLEL to FHIR parallel study design",
              "id": "f433d525-f2ef-40c8-9589-590507f006dd"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "none",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"masking\": \"NONE\"",
              "mapping_rationale": "Direct mapping of NONE to FHIR no masking type",
              "id": "ffeefa54-200a-4533-956b-2f259822a7cb"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Breast Cancer",
              "mapping_rationale": "Direct mapping of 'Breast Cancer' to SNOMED CT code for malignant neoplasm of breast, which is a core mCODE CancerCondition element",
              "id": "7210b40c-798c-4182-b534-896ac4a87d78"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.85,
              "source_text_fragment": "Early-stage Breast Cancer",
              "mapping_rationale": "'Early-stage Breast Cancer' mapped to SNOMED CT code for malignant tumor of early breast, indicating stage information for the CancerCondition",
              "id": "40d59fb9-c4df-48ec-938a-8191f561449a"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "female",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Females aged 18 to 70 years",
              "mapping_rationale": "Text explicitly states female gender for patient population",
              "id": "b535a14c-5fb0-42f5-806a-d28badcf2e36"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "active",
              "mapping_confidence": 0.9,
              "source_text_fragment": "histologically confirmed HR+/HER2- invasive breast cancer",
              "mapping_rationale": "Clear diagnosis of invasive breast cancer with specific biomarker status",
              "id": "1e6d35af-5a4a-4090-8c90-76815e1643c8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "positive",
              "mapping_confidence": 0.95,
              "source_text_fragment": "ER expression >50% by immunohistochemistry",
              "mapping_rationale": "ER expression >50% indicates positive estrogen receptor status",
              "id": "ad741e6c-eec1-496f-974e-be8cb4820183"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "negative",
              "mapping_confidence": 0.95,
              "source_text_fragment": "HER-2 negativity is defined as HER-2 results of 0 or 1+ by immunohistochemistry, or negative by FISH",
              "mapping_rationale": "Explicit HER2 negative status definition provided",
              "id": "5c35a304-33eb-40a7-9056-ee6bc8429aae"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": ">=20%",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Ki67\u2265+20%",
              "mapping_rationale": "Ki-67 proliferation index specified as \u226520%",
              "id": "da95fa52-f812-4944-a92a-c70f7862c4b6"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerstage",
                "display": "CancerStage"
              },
              "value": "T2N1M0",
              "mapping_confidence": 1.0,
              "source_text_fragment": "T2N1M0",
              "mapping_rationale": "Exact TNM staging provided in text",
              "id": "a6546832-6f43-49c0-9c54-7ab1ffabf2fb"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": ">=1500/mm3",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Absolute neutrophil count (ANC) \u2265 1,500/mm3",
              "mapping_rationale": "ANC laboratory value with threshold for eligibility",
              "id": "32cf01b2-93e3-4702-b7f0-e5a3527989d8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": ">=100000/mm3",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Platelet count (PLT) \u2265 100,000/mm3",
              "mapping_rationale": "Platelet count laboratory value with threshold for eligibility",
              "id": "1a76bb14-441d-4f68-8564-b311d836558d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": ">=9 g/dL",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Hemoglobin (Hb) \u2265 9 g/dL",
              "mapping_rationale": "Hemoglobin laboratory value with threshold for eligibility",
              "id": "151a0495-c28a-4b92-9cfd-c491748c822c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "<=1.5x ULN",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Serum creatinine \u2264 1.5 times the upper limit of normal (ULN)",
              "mapping_rationale": "Creatinine laboratory value with threshold for eligibility",
              "id": "4768f758-d7c8-4841-b94f-0d99785974f4"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "breast cancer",
              "mapping_confidence": 0.95,
              "source_text_fragment": "breast cancer",
              "mapping_rationale": "Text explicitly mentions breast cancer as the primary condition being studied",
              "id": "88f51d53-91e4-4115-bc87-a6fbb9312c62"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "early-stage",
              "mapping_confidence": 0.9,
              "source_text_fragment": "early-stage HR+/HER2- breast cancer",
              "mapping_rationale": "Text specifies early-stage breast cancer as the disease status being studied",
              "id": "53d920c3-60ba-4003-b735-31084ec9b007"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "Ki-67 expression",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Ki-67 expression",
              "mapping_rationale": "Ki-67 is explicitly mentioned as a tumor marker being measured and monitored",
              "id": "2eea9ab1-b57b-4c7c-b58a-a2f120ad1d10"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "EPclin multigene risk analysis",
              "mapping_confidence": 0.85,
              "source_text_fragment": "EPclin multigene risk analysis",
              "mapping_rationale": "EPclin is described as a 12-gene assay for multigene testing and risk stratification",
              "id": "51fc01ab-5d1d-4003-85af-1a8c44b61186"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarkerTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarkertest",
                "display": "TumorMarkerTest"
              },
              "value": "HER2-negative",
              "mapping_confidence": 0.95,
              "source_text_fragment": "HER2-",
              "mapping_rationale": "HER2-negative status is explicitly stated as an inclusion criterion",
              "id": "f23a8146-ff51-4308-ab19-08eb665b5e6d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarkerTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarkertest",
                "display": "TumorMarkerTest"
              },
              "value": "hormone receptor-positive",
              "mapping_confidence": 0.95,
              "source_text_fragment": "hormone receptor-positive (HR+)",
              "mapping_rationale": "HR+ status is explicitly stated as an inclusion criterion for the study population",
              "id": "8de48aeb-c035-43d7-93b6-b9592c16197d"
            },
            {
              "resourceType": "MedicationStatement",
              "Mcode_element": "CancerRelatedMedication",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedication",
                "display": "CancerRelatedMedication"
              },
              "value": "palbociclib",
              "mapping_confidence": 0.9,
              "source_text_fragment": "palbociclib",
              "mapping_rationale": "Palbociclib is mentioned as a CDK4/6 inhibitor being studied in neoadjuvant therapy",
              "id": "92ee53ab-b8da-4fae-b0ad-bda5bb341a6d"
            },
            {
              "resourceType": "MedicationStatement",
              "Mcode_element": "CancerRelatedMedication",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedication",
                "display": "CancerRelatedMedication"
              },
              "value": "ribociclib",
              "mapping_confidence": 0.9,
              "source_text_fragment": "ribociclib",
              "mapping_rationale": "Ribociclib is mentioned as a CDK4/6 inhibitor being studied in neoadjuvant therapy",
              "id": "fa0b4561-e532-473d-9c73-5717bd99f59d"
            },
            {
              "resourceType": "MedicationStatement",
              "Mcode_element": "CancerRelatedMedication",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedication",
                "display": "CancerRelatedMedication"
              },
              "value": "abemaciclib",
              "mapping_confidence": 0.9,
              "source_text_fragment": "abemaciclib",
              "mapping_rationale": "Abemaciclib is mentioned as a CDK4/6 inhibitor being studied in neoadjuvant therapy",
              "id": "a156916a-79f7-469b-a4c4-5f74c1296ea7"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "neoadjuvant therapy",
              "mapping_confidence": 0.95,
              "source_text_fragment": "neoadjuvant therapy",
              "mapping_rationale": "The study focuses on neoadjuvant therapy for breast cancer patients",
              "id": "ffb4ca8e-811b-479a-91ea-810cd0f46de3"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "HR+/HER2- Breast Cancer",
              "mapping_confidence": 0.9,
              "source_text_fragment": "HR+/HER2- Breast Cancer",
              "mapping_rationale": "Text explicitly states breast cancer diagnosis with hormone receptor positive and HER2 negative subtype",
              "id": "7e0ff342-26d6-4597-b80b-729079759e99"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Negative",
              "mapping_confidence": 0.9,
              "source_text_fragment": "HER2-",
              "mapping_rationale": "HER2- indicates negative HER2 receptor status, a key biomarker in breast cancer",
              "id": "561e2d58-0cf4-43f1-9fa2-ba9dc8bf8345"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Positive",
              "mapping_confidence": 0.9,
              "source_text_fragment": "HR+",
              "mapping_rationale": "HR+ indicates positive hormone receptor status (estrogen and/or progesterone receptors)",
              "id": "46381a9d-0598-4ca5-bd01-ae642f03ee7d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedLaboratoryTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedlaboratorytest",
                "display": "CancerRelatedLaboratoryTest"
              },
              "value": "Dynamic Assessment",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Ki-67 Dynamic Assessment",
              "mapping_rationale": "Ki-67 is a proliferation marker used in breast cancer assessment, dynamic assessment implies serial measurements",
              "id": "05adbf7e-0aa7-4a42-b87b-1bceb82cb230"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "Multigene Risk Score",
              "mapping_confidence": 0.85,
              "source_text_fragment": "Multigene Risk Score",
              "mapping_rationale": "Multigene risk score implies genomic variant assessment for risk stratification in breast cancer",
              "id": "23afcd71-849f-4f2b-a978-77172bc11d15"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "CDK4/6 Inhibitors",
              "mapping_confidence": 0.95,
              "source_text_fragment": "CDK4/6 Inhibitors",
              "mapping_rationale": "Explicit mention of CDK4/6 inhibitors as cancer treatment medication",
              "id": "b7a0f239-2d18-4083-89cc-4b90174bc453"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "Endocrine Therapy",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Endocrine Therapy",
              "mapping_rationale": "Explicit mention of endocrine therapy as cancer treatment for hormone receptor positive breast cancer",
              "id": "35d35fce-a251-4345-92d5-c019337369ab"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "Neoadjuvant Treatment",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Neoadjuvant",
              "mapping_rationale": "Neoadjuvant therapy implies pre-surgical treatment, often involving surgical procedures",
              "id": "8ce5e4fc-d36a-424c-b6e2-fef4e604edef"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerClinicalTrial",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerclinicaltrial",
                "display": "CancerClinicalTrial"
              },
              "value": "Randomize-controlled Study",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Randomize-controlled Study",
              "mapping_rationale": "Explicit mention of randomized controlled clinical trial design",
              "id": "98de053b-6e6c-4bf2-9245-f4f52fb5e4f2"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerClinicalTrial",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerclinicaltrial",
                "display": "CancerClinicalTrial"
              },
              "value": "NCT06650748",
              "mapping_confidence": 1.0,
              "source_text_fragment": "nctId: NCT06650748",
              "mapping_rationale": "Explicit NCT ID provided for clinical trial identification",
              "id": "83e26ad1-ff7c-412c-a5fe-6fbb33d824b7"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 36,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 596,
              "completion_tokens": 1334,
              "total_tokens": 1930
            },
            "aggregate_token_usage": {
              "prompt_tokens": 3831,
              "completion_tokens": 4358,
              "total_tokens": 8189,
              "model_name": "deepseek-coder",
              "provider_name": "deepseek"
            }
          }
        },
        {
          "trial_id": "NCT00109785",
          "processing_time": 207.66646599769592,
          "mcode_mappings": [
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedresearchstudy",
                "display": "CancerRelatedResearchStudy"
              },
              "value": "DIAGNOSTIC",
              "mapping_confidence": 0.9,
              "source_text_fragment": "\"primaryPurpose\": \"DIAGNOSTIC\"",
              "mapping_rationale": "Primary purpose of diagnostic maps to ResearchStudy with diagnostic type in mCODE CancerRelatedResearchStudy",
              "id": "9b5cda97-32db-448c-bcbd-475f744a73ab"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedresearchstudy",
                "display": "CancerRelatedResearchStudy"
              },
              "value": "SINGLE_GROUP",
              "mapping_confidence": 0.9,
              "source_text_fragment": "\"interventionModel\": \"SINGLE_GROUP\"",
              "mapping_rationale": "Single group intervention model maps to single-group design in ResearchStudy for mCODE CancerRelatedResearchStudy",
              "id": "7c4ef4b9-e2b5-4e47-8cc1-9976b5cf653e"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedresearchstudy",
                "display": "CancerRelatedResearchStudy"
              },
              "value": "NONE",
              "mapping_confidence": 0.9,
              "source_text_fragment": "\"masking\": \"NONE\"",
              "mapping_rationale": "No masking specified maps to none masking type in ResearchStudy for mCODE CancerRelatedResearchStudy",
              "id": "bf5d80a4-2c0f-474b-94b8-b0a279dccb81"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "active",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Breast Cancer",
              "mapping_rationale": "Text 'Breast Cancer' directly maps to SNOMED CT code for malignant neoplasm of breast, which is the primary cancer condition in mCODE",
              "id": "bf5a12c1-156c-4cb8-8aff-ef02448fad5c"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "confirmed",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Histologically confirmed locally advanced breast carcinoma",
              "mapping_rationale": "Direct mapping to SNOMED CT code for locally advanced breast cancer with histological confirmation",
              "id": "2dceb8f4-2d7f-4c1f-8c67-2942faebc6cf"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerStageGroup",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerstagegroup",
                "display": "CancerStageGroup"
              },
              "value": "T3-T4, N2-N3",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stage T3 T4, N2 or N3 disease",
              "mapping_rationale": "Direct mapping of TNM staging information for breast cancer",
              "id": "3ec19e66-3053-4152-b784-a8e0c2037081"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "unknown",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Hormone receptor status: Not specified",
              "mapping_rationale": "Hormone receptor status is a key mCODE element but not specified in source text",
              "id": "872ea449-0cdc-47e1-8c98-465e50858d83"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Patient",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patient",
                "display": "Patient"
              },
              "value": "unknown",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Sex: Male or female",
              "mapping_rationale": "Sex is specified but not specific to patient, mapped as unknown for individual patient",
              "id": "52a0ab4b-08ce-478a-8bbc-670ccfe9bca5"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ECOGPerformanceStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "ecogperformancestatus",
                "display": "ECOGPerformanceStatus"
              },
              "value": "80-100%",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Karnofsky 80-100%",
              "mapping_rationale": "Direct mapping of Karnofsky performance status score",
              "id": "7708724f-1d93-4f4c-9e25-7e20074267c5"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "absent",
              "mapping_confidence": 0.9,
              "source_text_fragment": "No history of psychiatric illness that would preclude giving informed consent",
              "mapping_rationale": "Mapping absence of psychiatric comorbidity that could affect treatment",
              "id": "03b67009-c66a-4a44-833e-a5b036e2be60"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PregnancyStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "pregnancystatus",
                "display": "PregnancyStatus"
              },
              "value": "not_pregnant",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Not pregnant",
              "mapping_rationale": "Direct mapping of pregnancy status for female patients",
              "id": "a09da78c-47bd-4e60-b480-b431ec97d915"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ContraceptiveUse",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "contraceptiveuse",
                "display": "ContraceptiveUse"
              },
              "value": "effective",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Fertile patients must use effective contraception",
              "mapping_rationale": "Mapping contraceptive requirement for fertile patients",
              "id": "0d3f9e09-ae38-402d-95c2-78c781121c68"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "unknown",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Surgery: Not specified",
              "mapping_rationale": "Surgical history is not specified but is relevant mCODE element",
              "id": "f74971aa-070a-42ab-87d3-65f8737f27ff"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Radiotherapy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "radiotherapy",
                "display": "Radiotherapy"
              },
              "value": "unknown",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Radiotherapy: Not specified",
              "mapping_rationale": "Radiotherapy history is not specified but is relevant mCODE element",
              "id": "f592b8ad-bc9c-403f-b03b-51f9bff99c7a"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "active",
              "mapping_confidence": 0.95,
              "source_text_fragment": "patients with locally advanced breast cancer",
              "mapping_rationale": "Text explicitly states 'locally advanced breast cancer' which maps to SNOMED CT code for locally advanced malignant neoplasm of breast",
              "id": "3efe80dc-a66f-4894-a682-1b7362d3ad16"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "planned",
              "mapping_confidence": 0.9,
              "source_text_fragment": "surgical resection of the tumor",
              "mapping_rationale": "Text mentions surgical resection of tumor as part of treatment plan after chemotherapy",
              "id": "295a34d9-a2ec-42f2-9cd8-d5393dae5f26"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Radiotherapy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "radiotherapy",
                "display": "Radiotherapy"
              },
              "value": "planned",
              "mapping_confidence": 0.9,
              "source_text_fragment": "the patient may be offered radiation therapy",
              "mapping_rationale": "Text mentions radiation therapy as potential treatment option if tumor is unresectable",
              "id": "c9f681e0-2cdc-4121-b7fe-761c497d9eeb"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorSize",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumorsize",
                "display": "TumorSize"
              },
              "value": "monitored",
              "mapping_confidence": 0.85,
              "source_text_fragment": "change in tumor dimension",
              "mapping_rationale": "Multiple references to monitoring tumor size/dimension changes as part of study objectives",
              "id": "ab168ffc-72d9-4447-a839-0684e5ea1807"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "assessed",
              "mapping_confidence": 0.88,
              "source_text_fragment": "patients whose tumor shrinks after treatment in comparison to patients whose tumor is stable or continues to grow",
              "mapping_rationale": "Text describes assessment of tumor response categories (shrink, stable, grow) which is core to disease status monitoring",
              "id": "3286506f-7b59-431b-88ba-811e00d54251"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Imaging",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "imaging",
                "display": "Imaging"
              },
              "value": "PET scan",
              "mapping_confidence": 0.95,
              "source_text_fragment": "PET scans",
              "mapping_rationale": "Multiple explicit references to PET scans as primary imaging modality throughout the text",
              "id": "687a8611-44a7-4361-afb7-e5fb1cef4bf8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "administered",
              "mapping_confidence": 0.92,
              "source_text_fragment": "chemotherapy administered",
              "mapping_rationale": "Text explicitly states chemotherapy is administered as part of treatment regimen",
              "id": "2275bff5-02cf-4ec9-9ff5-577abfa0a90b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "DNA incorporation analysis",
              "mapping_confidence": 0.8,
              "source_text_fragment": "incorporation of IUdR into tumor is in the tumor DNA at 24-36 hours post injection, as documented by tissue analysis and immunohistochemistry",
              "mapping_rationale": "Text mentions DNA incorporation analysis through tissue analysis and immunohistochemistry",
              "id": "12482ff9-a00c-4a6a-ac9c-1d27e0340bf7"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "measured",
              "mapping_confidence": 0.85,
              "source_text_fragment": "proliferative activity of the tumor",
              "mapping_rationale": "Text explicitly mentions assessment of proliferative activity as a study objective",
              "id": "1dba220f-16c0-41e3-a520-b0b6c32ae069"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "active",
              "mapping_confidence": 0.98,
              "source_text_fragment": "This clinical trial is studying",
              "mapping_rationale": "Text explicitly describes a clinical trial with objectives, procedures, and patient accrual",
              "id": "87fa7c69-c7fa-47fd-a872-f9cae61d3760"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Locally Advanced Breast Cancer",
              "mapping_rationale": "Text explicitly mentions 'Locally Advanced Breast Cancer' which maps to SNOMED CT code for malignant neoplasm of breast",
              "id": "42db746e-7ddd-4bca-a033-2c1eeaaa95c0"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "planned",
              "mapping_confidence": 0.95,
              "source_text_fragment": "PET Scans",
              "mapping_rationale": "'PET Scans' refers to Positron Emission Tomography, a diagnostic imaging procedure for cancer assessment",
              "id": "61bc1340-721c-4df9-9f76-0f3433eb075c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "monitored",
              "mapping_confidence": 0.85,
              "source_text_fragment": "to Follow DNA Metabolism",
              "mapping_rationale": "Text mentions monitoring DNA metabolism, which is a tumor marker assessment using I-124-Iododeoxyuridine tracer",
              "id": "9a8c2afe-59c9-4748-8c40-4d2450b729cd"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "monitored",
              "mapping_confidence": 0.85,
              "source_text_fragment": "Tracer for Glycolysis",
              "mapping_rationale": "Text mentions glycolysis as a metabolic marker being tracked using 18-F-2-Fluoro-2-Deoxy-(D)-Glucose tracer",
              "id": "1efd094e-b65c-4ada-9903-8f3a9f8b7323"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "administered",
              "mapping_confidence": 0.8,
              "source_text_fragment": "I-124-Iododeoxyuridine",
              "mapping_rationale": "I-124-Iododeoxyuridine is a radiopharmaceutical agent used for PET imaging to track DNA metabolism",
              "id": "0ebfc58c-3ffa-4e54-a8e1-48005e6bab75"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "administered",
              "mapping_confidence": 0.8,
              "source_text_fragment": "18-F-2-Fluoro-2-Deoxy-(D)-Glucose",
              "mapping_rationale": "18-F-2-Fluoro-2-Deoxy-(D)-Glucose is FDG, a standard radiopharmaceutical for PET imaging to assess glycolysis",
              "id": "2d7bcfd7-59d8-47f1-be6f-d3469d369e18"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "planned",
              "mapping_confidence": 0.7,
              "source_text_fragment": "Tumor Samples",
              "mapping_rationale": "Reference to 'Tumor Samples' implies biopsy procedure will be performed to obtain tumor tissue for analysis",
              "id": "b9cc8002-b49c-4abd-9f94-a5677d5e610e"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorSize",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumorsize",
                "display": "TumorSize"
              },
              "value": "assessed",
              "mapping_confidence": 0.6,
              "source_text_fragment": "Locally Advanced Breast Cancer",
              "mapping_rationale": "'Locally Advanced' implies tumor size and extent will be assessed through the imaging procedures described",
              "id": "05bd6ecb-b122-4e0b-91e0-449fb9e146f2"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "under_investigation",
              "mapping_confidence": 0.5,
              "source_text_fragment": "Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis",
              "mapping_rationale": "Study comparing metabolic tracers suggests potential investigation of genomic variants related to DNA metabolism and glycolysis pathways",
              "id": "860957eb-96f6-4512-ae77-31970cd09a8b"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 33,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 577,
              "completion_tokens": 1281,
              "total_tokens": 1858
            },
            "aggregate_token_usage": {
              "prompt_tokens": 3356,
              "completion_tokens": 4493,
              "total_tokens": 7849,
              "model_name": "deepseek-coder",
              "provider_name": "deepseek"
            }
          }
        },
        {
          "trial_id": "NCT00616135",
          "processing_time": 240.26113414764404,
          "mcode_mappings": [
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "TREATMENT",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"primaryPurpose\": \"TREATMENT\"",
              "mapping_rationale": "Primary purpose of TREATMENT maps directly to ResearchStudy with treatment type",
              "id": "c3043986-4195-4a1c-bc9b-c1a526662563"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "NON_RANDOMIZED",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"allocation\": \"NON_RANDOMIZED\"",
              "mapping_rationale": "Allocation method NON_RANDOMIZED maps to non-randomized allocation type in ResearchStudy",
              "id": "c68818cb-c327-4dec-bb26-7fb95e6dc072"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "SINGLE_GROUP",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"interventionModel\": \"SINGLE_GROUP\"",
              "mapping_rationale": "Intervention model SINGLE_GROUP maps to single-group design in ResearchStudy",
              "id": "f4bfea3c-8f10-4a5f-b4c2-d94d4a9ef013"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "NONE",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"masking\": \"NONE\"",
              "mapping_rationale": "Masking type NONE maps to no masking in ResearchStudy blinding",
              "id": "ed6c2759-a85d-4de9-971b-854932085dc0"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Breast Neoplasms",
              "mapping_rationale": "Breast Neoplasms maps to SNOMED CT code for malignant neoplasm of breast, which is a primary cancer condition in mCODE",
              "id": "bbda803b-4447-478f-82aa-9a4f8eb41203"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Carcinoma, Ductal, Breast",
              "mapping_rationale": "Ductal carcinoma of breast is a specific histological type of breast cancer, mapped to SNOMED CT adenocarcinoma code",
              "id": "619d4635-af23-49cc-907c-cfa6669acc7e"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "performed",
              "mapping_confidence": 0.7,
              "source_text_fragment": "Mammaplasty",
              "mapping_rationale": "Mammaplasty is a breast surgical procedure that may be cancer-related, mapped to SNOMED CT code",
              "id": "eaf1d661-4a40-44df-bd86-d71eec4b07d5"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "performed",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Mastectomy",
              "mapping_rationale": "Mastectomy is a definitive cancer-related surgical procedure for breast cancer treatment",
              "id": "19a98add-ed2d-4dd9-ae48-4a87de35ceb0"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "performed",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Mastectomy, Segmental",
              "mapping_rationale": "Segmental mastectomy is a specific type of breast cancer surgery, mapped to SNOMED CT code",
              "id": "c5ce04b3-1ab2-4cb2-8125-7941532f96a1"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "performed",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Lumpectomy",
              "mapping_rationale": "Lumpectomy is a breast-conserving surgical procedure commonly used in breast cancer treatment",
              "id": "5462e9b5-4965-495b-8003-d36a168aaa5c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "performed",
              "mapping_confidence": 0.7,
              "source_text_fragment": "Breast Reconstruction",
              "mapping_rationale": "Breast reconstruction is a surgical procedure often performed following mastectomy for breast cancer",
              "id": "0a559afa-06e0-4495-b600-f82ffaea596f"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "T2N0M0",
              "mapping_confidence": 0.9,
              "source_text_fragment": "T2N0M0 breast carcinoma",
              "mapping_rationale": "T2N0M0 staging indicates early breast cancer with tumor size \u22643cm, no lymph node involvement, and no distant metastasis",
              "id": "7bd5c3e4-96d0-481a-bf6e-7f6124e86cfe"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerStageGroup",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerstagegroup",
                "display": "CancerStageGroup"
              },
              "value": "Stage IIA",
              "mapping_confidence": 0.8,
              "source_text_fragment": "T2N0M0 breast carcinoma",
              "mapping_rationale": "T2N0M0 corresponds to AJCC Stage IIA for breast cancer",
              "id": "e4b46e4c-d807-4305-9d72-c3c8eebd6565"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "completed",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)",
              "mapping_rationale": "Segmental mastectomy and quadrantectomy are breast-conserving surgical procedures for breast cancer",
              "id": "bb0dee25-1749-445b-832e-45de1f718956"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "No evidence of disease",
              "mapping_confidence": 0.9,
              "source_text_fragment": "absence of recurrence",
              "mapping_rationale": "Absence of recurrence indicates no evidence of disease following treatment",
              "id": "4a819bd5-b677-45e6-b959-45ac1f881fa4"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PerformanceStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "performancestatus",
                "display": "PerformanceStatus"
              },
              "value": "Able to carry out normal activity",
              "mapping_confidence": 0.7,
              "source_text_fragment": "Ability to undergo lipoaspiration",
              "mapping_rationale": "Ability to undergo surgical procedure suggests adequate performance status",
              "id": "68b6ef59-9c06-4937-ad96-313baea53a03"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "Absent",
              "mapping_confidence": 0.95,
              "source_text_fragment": "History of autoimmune disorder (e.g., Systemic Lupus Erythematosus [SLE])",
              "mapping_rationale": "Exclusion criteria specifies no history of autoimmune disorders",
              "id": "72ec4d8d-e50b-4f2f-8c5a-d35c3540aa27"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Comorbidity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "comorbidity",
                "display": "Comorbidity"
              },
              "value": "Absent",
              "mapping_confidence": 0.95,
              "source_text_fragment": "History of keloid scarring",
              "mapping_rationale": "Exclusion criteria specifies no history of keloid scarring",
              "id": "3b8e6ebf-0d89-446a-88d8-612f8563f6f1"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationStatement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationstatement",
                "display": "CancerRelatedMedicationStatement"
              },
              "value": "Not taking",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Chronic use (>7 consecutive days) of anticoagulants (such as aspirin) or NSAIDs within 15 days prior to enrollment",
              "mapping_rationale": "Exclusion criteria prohibits chronic anticoagulant/NSAID use prior to enrollment",
              "id": "e43a5b85-1eed-4580-984d-e18248a41d0f"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "BodyMassIndex",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "bodymassindex",
                "display": "BodyMassIndex"
              },
              "value": "\u226430",
              "mapping_confidence": 0.95,
              "source_text_fragment": "Body Mass Index (BMI) >30",
              "mapping_rationale": "Exclusion criteria specifies BMI must be \u226430 for eligibility",
              "id": "62b37f8c-d94b-4b8f-b8ee-34ba1ec5c5f3"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "No evidence of disease",
              "mapping_confidence": 0.9,
              "source_text_fragment": "No evidence of recurrence of cancer based on mammogram or breast exam prior to enrollment",
              "mapping_rationale": "No evidence of recurrence confirmed by imaging and physical examination",
              "id": "e429444c-0afa-4f93-81ae-c0d7a01414d4"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedresearchstudy",
                "display": "CancerRelatedResearchStudy"
              },
              "value": "post-marketing study",
              "mapping_confidence": 0.9,
              "source_text_fragment": "A post-marketing study",
              "mapping_rationale": "Text describes a research study type which maps to mCODE CancerRelatedResearchStudy element using LOINC code for post-marketing studies",
              "id": "012cff19-c762-467e-870e-030b005f7acd"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "transplantation of autologous fat",
              "mapping_confidence": 0.95,
              "source_text_fragment": "transplantation of autologous fat",
              "mapping_rationale": "Describes a surgical procedure involving transplantation, mapped to SNOMED CT code for autologous fat transplantation",
              "id": "c4a6a196-5053-48f2-a3a4-4f01f5e7cdf9"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "Adipose Derived Regenerative Cells",
              "mapping_confidence": 0.85,
              "source_text_fragment": "Adipose Derived Regenerative Cells (ADRCs)",
              "mapping_rationale": "ADRCs are a therapeutic cellular product used in cancer-related procedures, mapped using SNOMED CT code for adipose-derived regenerative cells",
              "id": "16243441-8c4e-4c4a-93e0-196dcac57e8f"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "breast cancer",
              "mapping_confidence": 0.8,
              "source_text_fragment": "breast deformities post segmental mastectomy or quadrantectomy",
              "mapping_rationale": "Context implies breast cancer treatment (mastectomy/quadrantectomy) for breast deformities, mapped to SNOMED CT breast cancer code",
              "id": "b7c00c19-bcaf-4503-b038-b71d3a2a5521"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "segmental mastectomy",
              "mapping_confidence": 0.9,
              "source_text_fragment": "segmental mastectomy",
              "mapping_rationale": "Explicit mention of segmental mastectomy procedure, mapped to SNOMED CT code for this specific breast surgery",
              "id": "ddb84a44-78b3-46e8-8a83-e5b437574dcb"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "quadrantectomy",
              "mapping_confidence": 0.9,
              "source_text_fragment": "quadrantectomy (lumpectomy)",
              "mapping_rationale": "Explicit mention of quadrantectomy procedure, mapped to SNOMED CT code for breast quadrantectomy",
              "id": "f677f3ac-78f5-495b-928f-1c98c720e7db"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "breast deformity",
              "mapping_confidence": 0.85,
              "source_text_fragment": "breast deformities",
              "mapping_rationale": "Describes breast deformities as a condition resulting from cancer treatment, mapped to SNOMED CT code for breast deformity",
              "id": "7549ccf0-e39b-45c2-9916-1636b2953728"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy",
                "display": "ResearchStudy"
              },
              "value": "NCT00616135",
              "mapping_confidence": 1.0,
              "source_text_fragment": "nctId: NCT00616135",
              "mapping_rationale": "NCT ID directly maps to ResearchStudy.identifier with clinicaltrials.gov system",
              "id": "5f9b2975-2078-4f9b-8bac-7ebc88e7c1e6"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy.title",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy.title",
                "display": "ResearchStudy.title"
              },
              "value": "Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "briefTitle: Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy",
              "mapping_rationale": "Brief title directly maps to ResearchStudy.title",
              "id": "cd0d7a44-0502-438c-884d-611ab4a4e14f"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy.title",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy.title",
                "display": "ResearchStudy.title"
              },
              "value": "A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study.",
              "mapping_confidence": 1.0,
              "source_text_fragment": "officialTitle: A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study.",
              "mapping_rationale": "Official title directly maps to ResearchStudy.title",
              "id": "42148a62-b0d7-47a0-815d-f7bbec50312b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ResearchStudy.phase",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "researchstudy.phase",
                "display": "ResearchStudy.phase"
              },
              "value": "phase-4",
              "mapping_confidence": 1.0,
              "source_text_fragment": "A Phase IV Post Market Study",
              "mapping_rationale": "Phase IV explicitly stated in the official title",
              "id": "43e786cd-7cc8-4e53-a4bd-01c5fb5a5709"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "present",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Breast Deformities After Lumpectomy",
              "mapping_rationale": "Lumpectomy implies previous breast cancer diagnosis and treatment",
              "id": "461545e3-48f4-4f16-a641-1cd88c1f89d2"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "completed",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Lumpectomy",
              "mapping_rationale": "Lumpectomy is explicitly mentioned as a previous surgical procedure",
              "id": "b37297f0-89b2-4793-b2ea-951caaa1ff8c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "planned",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Autologous Fat Enhanced w/ Regenerative Cells Transplanted",
              "mapping_rationale": "Study involves autologous fat transplantation procedure for reconstruction",
              "id": "ddba6198-1bb9-48ca-8b96-a2eb70222a14"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerDiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerdiseasestatus",
                "display": "CancerDiseaseStatus"
              },
              "value": "post-treatment",
              "mapping_confidence": 0.85,
              "source_text_fragment": "After Lumpectomy",
              "mapping_rationale": "Study focuses on reconstruction after cancer treatment, implying post-treatment status",
              "id": "b4b72440-7dd1-4c19-9263-15623211764c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "present",
              "mapping_confidence": 0.7,
              "source_text_fragment": "Adipose Derived Regenerative Cells",
              "mapping_rationale": "Study involves regenerative cells as a therapeutic approach, can be considered a tumor marker in reconstruction context",
              "id": "a88ae96f-3e87-4f07-9657-2fbf8f1bc25b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "planned",
              "mapping_confidence": 0.75,
              "source_text_fragment": "Adipose Derived Regenerative Cells",
              "mapping_rationale": "Regenerative cells are being administered as a therapeutic intervention",
              "id": "cff90429-8982-40f4-884a-21a14c3c713e"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 38,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 584,
              "completion_tokens": 1422,
              "total_tokens": 2006
            },
            "aggregate_token_usage": {
              "prompt_tokens": 3106,
              "completion_tokens": 5267,
              "total_tokens": 8373,
              "model_name": "deepseek-coder",
              "provider_name": "deepseek"
            }
          }
        }
      ],
      "quality_analysis": {
        "total_mappings": 214,
        "avg_confidence": 0.8960747663551408,
        "high_confidence_count": 196,
        "with_source_text": 194,
        "source_text_ratio": 0.9065420560747663,
        "confidence_distribution": {
          "high (0.8-1.0)": 196,
          "medium (0.5-0.8)": 18,
          "low (0.0-0.5)": 0
        },
        "quality_score": 0.9042242990654208
      }
    },
    "direct_mcode_evidence_based_concise": {
      "prompt_name": "direct_mcode_evidence_based_concise",
      "model_name": "deepseek-coder",
      "trials_processed": 5,
      "total_processing_time": 425.2224054336548,
      "trial_results": [
        {
          "trial_id": "NCT01922921",
          "processing_time": 0.03921103477478027,
          "mcode_mappings": [
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast Carcinoma",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Recurrent Breast Carcinoma",
              "mapping_rationale": "Direct statement of cancer diagnosis with recurrence status",
              "id": "226d89b6-0f48-47c8-a076-47620d4738b1"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "Stage IV",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stage IV Breast Cancer",
              "mapping_rationale": "Explicit staging information for breast cancer",
              "id": "63f20f46-fb53-4d91-beeb-fe3fd360667b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancermarker",
                "display": "CancerMarker"
              },
              "value": "HER2/Neu Positive",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER2/Neu Positive",
              "mapping_rationale": "Direct statement of HER2/Neu biomarker status",
              "id": "efec7f27-a52c-48eb-8e30-cec3450dc887"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "HER2+ breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Patients with stage IV HER2+ breast cancer treated to:",
              "mapping_rationale": "Direct statement of cancer diagnosis with HER2 status",
              "id": "799b6dbd-14de-4f50-8c5c-7f0e375d6b27"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "Stage IV",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Patients with stage IV HER2+ breast cancer treated to:",
              "mapping_rationale": "Explicit staging information provided",
              "id": "bce83148-0826-414b-9682-a7956e926e5b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "HER2ReceptorStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "her2receptorstatus",
                "display": "HER2ReceptorStatus"
              },
              "value": "HER2+",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER2 overexpression by immunohistochemistry (IHC) of 2+ or 3+ in the primary tumor or metastasis",
              "mapping_rationale": "Direct evidence of HER2 positive status with specific criteria",
              "id": "05a1229e-8198-41ff-8166-5bbe04f5ff9a"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "trastuzumab monotherapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy",
              "mapping_rationale": "Explicit medication name and treatment type",
              "id": "ee00aa7f-156d-4f6a-b7b9-6fa9ad83004c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "trastuzumab and pertuzumab combination therapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "or trastuzumab and pertuzumab combination therapy administered per standard of care",
              "mapping_rationale": "Explicit medication combination therapy",
              "id": "9d8e9900-1c72-4fbc-9661-ef17e784a46c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Age",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "age",
                "display": "Age"
              },
              "value": ">=18 years",
              "mapping_confidence": 1.0,
              "source_text_fragment": "minimumAge: 18 Years",
              "mapping_rationale": "Explicit minimum age requirement stated",
              "id": "b1c7bdfc-b9a9-490e-be33-b152f013cf0b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "ECOGPerformanceStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "ecogperformancestatus",
                "display": "ECOGPerformanceStatus"
              },
              "value": "<=2",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Patients must have Zubrod performance status score of =< 2",
              "mapping_rationale": "Direct statement of performance status requirement",
              "id": "ab321dea-1fed-41b4-819a-d601c4afdb3a"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "LVEF",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "lvef",
                "display": "LVEF"
              },
              "value": ">= lower limit of normal",
              "mapping_confidence": 0.9,
              "source_text_fragment": "normal left ventricular ejection fraction (LVEF) >= the lower limit of normal for the facility",
              "mapping_rationale": "Clear cardiac function requirement with specific LVEF criteria",
              "id": "b9557ad4-1ff5-4393-83a1-0d7eb962323d"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Stable bone only disease",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Stable bone only disease after definitive therapy",
              "mapping_rationale": "Direct reference to bone metastasis status",
              "id": "64714d51-e739-49d5-acaf-22a51218ffc8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "DiseaseStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "diseasestatus",
                "display": "DiseaseStatus"
              },
              "value": "No evidence of disease (NED)",
              "mapping_confidence": 1.0,
              "source_text_fragment": "No evidence of disease (NED), or Stable bone only disease after definitive therapy",
              "mapping_rationale": "Explicit disease status criteria for eligibility",
              "id": "1b35ef22-cc39-4998-86cf-ac0435a7128a"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
              "mapping_rationale": "Direct statement of cancer diagnosis with staging and biomarker status",
              "id": "49ead88d-526f-45ac-b759-4484f13a1b07"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "Stage IV",
              "mapping_confidence": 1.0,
              "source_text_fragment": "stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer",
              "mapping_rationale": "Explicit staging information provided for breast cancer",
              "id": "a10bc3df-ccc0-4c13-99af-d75546551837"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerBiomarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerbiomarker",
                "display": "CancerBiomarker"
              },
              "value": "HER2 positive",
              "mapping_confidence": 1.0,
              "source_text_fragment": "human epidermal growth factor receptor 2 (HER2) positive breast cancer",
              "mapping_rationale": "Direct statement of HER2 biomarker status",
              "id": "c14117e7-5fa7-43ab-8b2b-35edea96441f"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "trastuzumab",
              "mapping_confidence": 1.0,
              "source_text_fragment": "trastuzumab (or trastuzumab and pertuzumab) per standard of care",
              "mapping_rationale": "Explicit mention of trastuzumab as part of treatment regimen",
              "id": "d958b487-fe2a-447e-a962-7721d7f3f586"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "pertuzumab",
              "mapping_confidence": 0.9,
              "source_text_fragment": "trastuzumab (or trastuzumab and pertuzumab) per standard of care",
              "mapping_rationale": "Pertuzumab mentioned as alternative or combination therapy option",
              "id": "e4086ae8-8fa7-45ed-a8a0-0c365c905faa"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "polysaccharide-K",
              "mapping_confidence": 1.0,
              "source_text_fragment": "polysaccharide-K PO BID for 4 months",
              "mapping_rationale": "Direct mention of polysaccharide-K as investigational treatment",
              "id": "3ecf1db3-ce10-450c-89dd-601956299b0b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "HER2 ICD peptide-based vaccine",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER2 ICD peptide-based vaccine intradermally (ID) once monthly for 3 months",
              "mapping_rationale": "Explicit description of vaccine therapy component",
              "id": "4660b963-2fcf-4e58-8fdd-156c543d4705"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "intradermally (ID)",
              "mapping_confidence": 0.8,
              "source_text_fragment": "HER2 ICD peptide-based vaccine intradermally (ID) once monthly for 3 months",
              "mapping_rationale": "Administration route specified for vaccine therapy",
              "id": "b057c4cb-69f9-47e2-8d25-82c9d2e733fc"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedMedicationAdministration",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedicationadministration",
                "display": "CancerRelatedMedicationAdministration"
              },
              "value": "orally (PO)",
              "mapping_confidence": 0.8,
              "source_text_fragment": "polysaccharide-K PO BID for 4 months",
              "mapping_rationale": "Administration route specified for polysaccharide-K",
              "id": "58898f17-54d7-40d4-a000-571e4aef4ff1"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Stage IV HER2 Positive Breast Cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stage IV HER2 Positive Breast Cancer",
              "mapping_rationale": "Direct statement of cancer diagnosis and stage",
              "id": "293544f7-3a8a-4da7-9c2c-763e8d357199"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "Stage IV",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stage IV HER2 Positive Breast Cancer",
              "mapping_rationale": "Explicit staging information provided",
              "id": "5667df83-ba4c-4b36-b2c0-8271c5fac0cc"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "HER2ReceptorStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "her2receptorstatus",
                "display": "HER2ReceptorStatus"
              },
              "value": "HER2 Positive",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stage IV HER2 Positive Breast Cancer",
              "mapping_rationale": "Direct statement of HER2 receptor status",
              "id": "3afdcea1-3348-48b8-b1ed-b6de96598b99"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "HER2-targeted monoclonal antibody therapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "receiving HER2-targeted monoclonal antibody therapy",
              "mapping_rationale": "Explicit statement of current treatment regimen",
              "id": "8139eba8-8eb8-4e88-a04b-3fac1bd3d722"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "HER2-targeted monoclonal antibody therapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "receiving HER2-targeted monoclonal antibody therapy",
              "mapping_rationale": "Direct statement of ongoing treatment",
              "id": "6b949395-ec5e-4405-ad43-a2ecd1d64d65"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientDemographics",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientdemographics",
                "display": "PatientDemographics"
              },
              "value": "Median 52 years (range 33-75)",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"Age, Continuous\" with median values of 52, 59, and 52 years across groups, with ranges from 33 to 75 years",
              "mapping_rationale": "Explicit age data provided with median and range values for all participant groups",
              "id": "6c0ce6b1-ae1e-4973-bc17-6578fd172c49"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientDemographics",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientdemographics",
                "display": "PatientDemographics"
              },
              "value": "Female: 31, Male: 0",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"Sex: Female, Male\" with values \"Female: 31\" and \"Male: 0\" for total group BG002",
              "mapping_rationale": "Explicit sex distribution data showing all participants are female",
              "id": "f78d4496-6ab7-4743-bd3a-f1974fb467f7"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientDemographics",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientdemographics",
                "display": "PatientDemographics"
              },
              "value": "Not Hispanic or Latino: 31",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"Ethnicity (NIH/OMB)\" with \"Not Hispanic or Latino: 31\" and all other categories showing 0 for total group",
              "mapping_rationale": "Explicit ethnicity data showing all participants are not Hispanic or Latino",
              "id": "0d6d8984-87ff-4603-8c63-4833109d07c6"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientDemographics",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientdemographics",
                "display": "PatientDemographics"
              },
              "value": "White: 27, Asian: 4",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"Race (NIH/OMB)\" with \"White: 27\" and \"Asian: 4\" for total group BG002, all other race categories show 0",
              "mapping_rationale": "Explicit race distribution data showing White and Asian participants only",
              "id": "59f0203d-5218-4909-8407-ade28ff79fd0"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Given per standard of care",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"Trastuzumab: Given per standard of care\" in both Arm I and Arm II descriptions",
              "mapping_rationale": "Explicit mention of trastuzumab administration as part of treatment regimen",
              "id": "dbf5aab7-4d0b-4dc9-a49f-d45aa5c7c50f"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Given per standard of care",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"Pertuzumab: Given per standard of care\" in both Arm I and Arm II descriptions",
              "mapping_rationale": "Explicit mention of pertuzumab administration as part of treatment regimen",
              "id": "a4893028-c7c0-45e3-b587-82e990f8d336"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "HER2 ICD peptide-based vaccine ID once monthly for 3 months",
              "mapping_confidence": 1.0,
              "source_text_fragment": "\"Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months\" in both Arm I and Arm II",
              "mapping_rationale": "Explicit description of HER2 vaccine administration schedule and route",
              "id": "fb753557-9073-4447-baba-0479dcdf5feb"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Trastuzumab",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Trastuzumab: Given per standard of care",
              "mapping_rationale": "Explicitly stated medication used in cancer treatment",
              "id": "dcd20227-92e4-4586-81b7-d13b2d8bf649"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Pertuzumab",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Pertuzumab: Given per standard of care",
              "mapping_rationale": "Explicitly stated medication used in cancer treatment",
              "id": "1017156b-5d59-4c86-ae22-6bd978cfecc8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "HER2 ICD peptide-based vaccine",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER2 ICD peptide-based vaccine ID once monthly for 3 months",
              "mapping_rationale": "Explicitly stated cancer vaccine treatment",
              "id": "0fd0d0e4-026c-446a-87eb-bf2849d1a3ea"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Toxicity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "toxicity",
                "display": "Toxicity"
              },
              "value": "Grade 3 or Higher Toxicity",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Number of Patients With Grade 3 or Higher Toxicity Per Study Arm",
              "mapping_rationale": "Explicitly stated toxicity grading using CTCAE criteria",
              "id": "66bdccab-b209-4c4f-b400-5e0cfc71aeeb"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Toxicity",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "toxicity",
                "display": "Toxicity"
              },
              "value": "Vomiting",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Only 1 patient of the 2 patients listed below had a possibly related event of vomiting",
              "mapping_rationale": "Explicitly stated adverse event of vomiting, though relationship to treatment is qualified as 'possibly related'",
              "id": "387bab3e-99c8-4e32-b89c-a79a7b67ff41"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Biomarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "biomarker",
                "display": "Biomarker"
              },
              "value": "Interferon (IFN)-Gamma Production",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Induction of Interferon (IFN)-Gamma Production and Cluster of Differentiation (CD)107a Expression in NK Cells",
              "mapping_rationale": "Explicitly stated biomarker measurement for immune response assessment",
              "id": "eef4feef-90b1-4b1e-b956-ba19eda74fd6"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Biomarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "biomarker",
                "display": "Biomarker"
              },
              "value": "CD107a Expression",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Induction of Interferon (IFN)-Gamma Production and Cluster of Differentiation (CD)107a Expression in NK Cells",
              "mapping_rationale": "Explicitly stated biomarker measurement for immune response assessment",
              "id": "25c8393b-8707-44c5-beea-ebee6016fda8"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 41,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 3247,
              "completion_tokens": 978,
              "total_tokens": 4225
            },
            "aggregate_token_usage": {
              "prompt_tokens": 0,
              "completion_tokens": 0,
              "total_tokens": 0,
              "model_name": "",
              "provider_name": ""
            }
          }
        },
        {
          "trial_id": "NCT01026116",
          "processing_time": 0.010127067565917969,
          "mcode_mappings": [
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast Neoplasms",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Conditions: Breast Neoplasms",
              "mapping_rationale": "Direct statement of cancer condition using standard oncology terminology",
              "id": "f740334e-5c29-43ee-860a-03c7493b6196"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientSex",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientsex",
                "display": "PatientSex"
              },
              "value": "Female",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Female patients, age 18~40",
              "mapping_rationale": "Explicitly states female patients",
              "id": "d5867156-afcc-4ded-bacb-c9cbfd4c50cb"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Adenocarcinoma of breast",
              "mapping_confidence": 1.0,
              "source_text_fragment": "histologically confirmed adenocarcinoma of the breast",
              "mapping_rationale": "Explicit diagnosis of breast adenocarcinoma",
              "id": "ff97085c-0dfa-4700-8426-226849a96c44"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "ER+ breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "estrogen-receptor positive (ER+) breast cancer",
              "mapping_rationale": "Explicit ER+ status confirmation",
              "id": "ab9d4b63-77d2-4ca5-a6f6-d5c9a38b739e"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "HER-2 negative",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test",
              "mapping_rationale": "Explicit HER-2 negative status",
              "id": "bffcc2ed-0b01-45e3-88d7-1026fd7aabdf"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "Stage I-III",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stage I-III",
              "mapping_rationale": "Explicit cancer stage range",
              "id": "73e4c7a6-5af8-4fe6-9c1e-31d3a493fc31"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorSize",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumorsize",
                "display": "TumorSize"
              },
              "value": ">10 mm or >20 mm",
              "mapping_confidence": 0.9,
              "source_text_fragment": "primary tumor diameter >10 mm when histological grade III, or tumor diameter >20 mm when histological grade II",
              "mapping_rationale": "Explicit tumor size criteria for high-risk factors",
              "id": "1e250be7-8853-4a7f-bca4-f1290cb50ee8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "LymphNodeInvolvement",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "lymphnodeinvolvement",
                "display": "LymphNodeInvolvement"
              },
              "value": "Node-positive or node-negative with high-risk factors",
              "mapping_confidence": 1.0,
              "source_text_fragment": "pathologically confirmed regional node-positive disease, or node-negative disease with high-risk factors",
              "mapping_rationale": "Explicit lymph node status criteria",
              "id": "ab307f1f-e802-451c-9f1e-1acb4b29616b"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Primary surgery with clear margins plus axillary dissection",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Primary surgery with clear margins plus axillary dissection",
              "mapping_rationale": "Explicit surgical treatment description",
              "id": "b2e39c8f-8b04-43ae-88ee-cbe8a7bb8f38"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Chemotherapy",
              "mapping_confidence": 0.8,
              "source_text_fragment": "negative in situ hybridization test by chemotherapy",
              "mapping_rationale": "Mentions chemotherapy in context of HER2 testing",
              "id": "f08481d7-f230-45fd-a165-ab86d5ed79af"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "young breast cancer patients are characterized by aggressive clinical history",
              "mapping_rationale": "Direct mention of breast cancer diagnosis",
              "id": "83680c65-c4aa-4d64-94bb-aa6003501495"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientAgeGroup",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientagegroup",
                "display": "PatientAgeGroup"
              },
              "value": "young",
              "mapping_confidence": 0.9,
              "source_text_fragment": "young breast cancer patients are characterized by aggressive clinical history",
              "mapping_rationale": "Explicit mention of young patient population",
              "id": "494fc6f6-fa3c-4fde-b396-3fef823b70c9"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "paclitaxel",
              "mapping_confidence": 1.0,
              "source_text_fragment": "different strategies incorporating paclitaxel to anthracycline-based regimens",
              "mapping_rationale": "Direct mention of paclitaxel as part of treatment regimen",
              "id": "9fa84e72-cfb7-45bf-8318-7c87182a5078"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "anthracycline-based regimens",
              "mapping_confidence": 1.0,
              "source_text_fragment": "different strategies incorporating paclitaxel to anthracycline-based regimens",
              "mapping_rationale": "Direct mention of anthracycline-based treatment regimens",
              "id": "d2f4e782-035f-46a3-bc45-b7399d022fb6"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast Cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Adjuvant Therapy for Operable Breast Cancer Patients",
              "mapping_rationale": "Direct mention of breast cancer in clinical context",
              "id": "de3adb38-0619-4d03-9e1f-6ec62c02f8c4"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Age",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "age",
                "display": "Age"
              },
              "value": "Less Than 40 Years Old",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Patients Less Than 40 Years Old",
              "mapping_rationale": "Explicit age range specification for patient population",
              "id": "9ee8fbfe-d3f6-4cfb-b0e7-aa50218b5f4d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "EC-wP",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Comparing EC-wP Versus EP-wP as Adjuvant Therapy",
              "mapping_rationale": "EC-wP is a recognized chemotherapy regimen for breast cancer",
              "id": "5a396c68-9134-4fec-af5c-1eee7f7b7daf"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "EP-wP",
              "mapping_confidence": 0.9,
              "source_text_fragment": "Comparing EC-wP Versus EP-wP as Adjuvant Therapy",
              "mapping_rationale": "EP-wP is a recognized chemotherapy regimen for breast cancer",
              "id": "b2621c60-a9da-40b1-8c57-5c47e2c0a232"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerConditionStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerconditionstatus",
                "display": "CancerConditionStatus"
              },
              "value": "Operable",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Operable Breast Cancer Patients",
              "mapping_rationale": "Direct statement that patients have operable breast cancer",
              "id": "7d5bdf23-0d77-420c-ab5c-674caa58ffe5"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 19,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 829,
              "completion_tokens": 650,
              "total_tokens": 1479
            },
            "aggregate_token_usage": {
              "prompt_tokens": 0,
              "completion_tokens": 0,
              "total_tokens": 0,
              "model_name": "",
              "provider_name": ""
            }
          }
        },
        {
          "trial_id": "NCT06650748",
          "processing_time": 153.0871741771698,
          "mcode_mappings": [
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast Cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Conditions: Breast Cancer",
              "mapping_rationale": "Direct, unambiguous statement of breast cancer diagnosis",
              "id": "5591890e-c7d1-4b04-90c7-4cd7148eb5ea"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Early-stage Breast Cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Early-stage Breast Cancer",
              "mapping_rationale": "Direct, unambiguous statement of early-stage breast cancer diagnosis",
              "id": "35058890-2868-4343-9aa4-1a4b333a7af9"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientSex",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientsex",
                "display": "PatientSex"
              },
              "value": "Female",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Females aged 18 to 70 years",
              "mapping_rationale": "Direct statement of female sex",
              "id": "59abcdad-eaec-4416-995b-acea9a27bf4d"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "HR+/HER2- invasive breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Patients with histologically confirmed HR+/HER2- invasive breast cancer",
              "mapping_rationale": "Direct statement of breast cancer diagnosis with hormone receptor status",
              "id": "ea449a0e-863a-422d-84b7-9a186367b819"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "T2N1M0",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Tumor diameter >2 cm, clinically positive axillary lymph nodes not more than 2 (T2N1M0)",
              "mapping_rationale": "Direct TNM staging classification provided",
              "id": "5a5f290e-62bc-49eb-812b-c272056bd7bf"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "Ki67\u2265+20%",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Ki67\u2265+20%",
              "mapping_rationale": "Direct statement of Ki-67 tumor marker level",
              "id": "58258ab3-cf09-41a3-9df8-90142b62f476"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "ER expression >50%",
              "mapping_confidence": 1.0,
              "source_text_fragment": "ER expression >50% by immunohistochemistry",
              "mapping_rationale": "Direct statement of estrogen receptor expression level",
              "id": "45f0b2d7-fd06-4060-8733-ccdbccff9462"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarker",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarker",
                "display": "TumorMarker"
              },
              "value": "HER-2 negative",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HER-2 negativity is defined as HER-2 results of 0 or 1+ by immunohistochemistry",
              "mapping_rationale": "Direct statement of HER2 negativity status",
              "id": "4e465fbc-0859-4a94-9160-692ee350244c"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Metastatic breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Metastatic breast cancer",
              "mapping_rationale": "Direct statement of metastatic breast cancer as exclusion criterion",
              "id": "0d0ae87c-1707-4386-be16-2ef342ae992a"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "China is a country with a high incidence of breast cancer.",
              "mapping_rationale": "Direct statement of cancer diagnosis",
              "id": "99aa811b-a8ab-4e61-9d23-1804088b6469"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "hormone receptor-positive (HR+) breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "For operable hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer",
              "mapping_rationale": "Explicit specification of hormone receptor status",
              "id": "1a33ec55-4556-4e2b-9287-dc624ce6f856"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "HER2-negative breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "human epidermal growth factor receptor 2-negative (HER2-) breast cancer",
              "mapping_rationale": "Direct statement of HER2 status",
              "id": "ef07f9c4-77a9-4a17-b3da-207d9d862884"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "early-stage breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "This study focuses on early-stage HR+/HER2- breast cancer",
              "mapping_rationale": "Explicit statement of cancer stage",
              "id": "905d74f6-c4b9-4164-abb3-b3306f89f3ef"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "palbociclib",
              "mapping_confidence": 1.0,
              "source_text_fragment": "the combination of palbociclib and letrozole significantly inhibited Ki-67 expression",
              "mapping_rationale": "Direct mention of specific CDK4/6 inhibitor medication",
              "id": "05626b77-7220-4074-bfcc-3ecea195a9f4"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "ribociclib",
              "mapping_confidence": 1.0,
              "source_text_fragment": "neoadjuvant endocrine therapy with palbociclib or ribociclib is comparable in efficacy",
              "mapping_rationale": "Direct mention of specific CDK4/6 inhibitor medication",
              "id": "79b95641-bf2f-4a66-af82-d94e94f5333f"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "abemaciclib",
              "mapping_confidence": 1.0,
              "source_text_fragment": "NeoMONARCH study suggests that a regimen containing abemaciclib is significantly superior",
              "mapping_rationale": "Direct mention of specific CDK4/6 inhibitor medication",
              "id": "17add870-6e8a-4b79-a187-0f78ee9c7d89"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "letrozole",
              "mapping_confidence": 1.0,
              "source_text_fragment": "the combination of palbociclib and letrozole significantly inhibited Ki-67 expression",
              "mapping_rationale": "Direct mention of endocrine therapy medication",
              "id": "7338f78e-c968-46f7-9d7c-c7bbf44ea324"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "anastrozole",
              "mapping_confidence": 1.0,
              "source_text_fragment": "significantly superior to anastrozole monotherapy, with statistical significance",
              "mapping_rationale": "Direct mention of endocrine therapy medication",
              "id": "12a31c83-bd4c-4f89-97cf-d3d530b91ca2"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarkerTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarkertest",
                "display": "TumorMarkerTest"
              },
              "value": "Ki-67 expression",
              "mapping_confidence": 1.0,
              "source_text_fragment": "the combination of palbociclib and letrozole significantly inhibited Ki-67 expression",
              "mapping_rationale": "Direct mention of tumor marker testing",
              "id": "c6e32a4b-00a8-4975-9a15-870a5fc84c7a"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "HR+/HER2- Breast Cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "HR+/HER2- Breast Cancer",
              "mapping_rationale": "Direct, unambiguous statement of cancer diagnosis with hormone receptor status",
              "id": "e7f174b6-92ee-4c86-a7fa-7c15b9e8fd13"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorMarkerTest",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumormarkertest",
                "display": "TumorMarkerTest"
              },
              "value": "Ki-67 Dynamic Assessment",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Ki-67 Dynamic Assessment",
              "mapping_rationale": "Explicit mention of Ki-67 tumor marker testing as part of the study protocol",
              "id": "e9987173-e717-40cf-8859-d95b4680f293"
            },
            {
              "resourceType": "MedicationStatement",
              "Mcode_element": "CancerRelatedMedication",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedication",
                "display": "CancerRelatedMedication"
              },
              "value": "CDK4/6 Inhibitors",
              "mapping_confidence": 1.0,
              "source_text_fragment": "CDK4/6 Inhibitors",
              "mapping_rationale": "Direct statement of CDK4/6 inhibitor medication being studied",
              "id": "6da7775a-8226-42ba-9ae1-00cfee0bb584"
            },
            {
              "resourceType": "MedicationStatement",
              "Mcode_element": "CancerRelatedMedication",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedication",
                "display": "CancerRelatedMedication"
              },
              "value": "Endocrine Therapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Endocrine Therapy",
              "mapping_rationale": "Explicit mention of endocrine therapy as a treatment modality",
              "id": "56ad60b4-1e4d-46af-839c-cd10e346df4e"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "GenomicVariant",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "genomicvariant",
                "display": "GenomicVariant"
              },
              "value": "Multigene Risk Score",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Multigene Risk Score",
              "mapping_rationale": "Direct statement of genomic testing using multigene risk assessment",
              "id": "edf97aa5-a49d-42fc-89d1-f2e64432009f"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 24,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 867,
              "completion_tokens": 676,
              "total_tokens": 1543
            },
            "aggregate_token_usage": {
              "prompt_tokens": 4915,
              "completion_tokens": 3245,
              "total_tokens": 8160,
              "model_name": "deepseek-coder",
              "provider_name": "deepseek"
            }
          }
        },
        {
          "trial_id": "NCT00109785",
          "processing_time": 118.37704706192017,
          "mcode_mappings": [
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast Cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Conditions: Breast Cancer",
              "mapping_rationale": "Direct, unambiguous statement of cancer diagnosis",
              "id": "40461279-fad9-4ba4-9793-fa78cb8d9011"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Locally advanced breast carcinoma",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Histologically confirmed locally advanced breast carcinoma",
              "mapping_rationale": "Direct statement of cancer diagnosis with histological confirmation",
              "id": "7d3678ae-03ed-4821-8cb3-44ba6d7800c5"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "T3 T4, N2 or N3 disease",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Stage T3 T4, N2 or N3 disease",
              "mapping_rationale": "Explicit TNM staging information provided",
              "id": "611091e5-1838-40fa-8f0a-16cf78725e8d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientAge",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientage",
                "display": "PatientAge"
              },
              "value": "18 and over",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Age: * 18 and over",
              "mapping_rationale": "Direct statement of minimum age requirement",
              "id": "462f747f-baf3-4fa7-a60a-a4904e6c36f3"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PatientSex",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "patientsex",
                "display": "PatientSex"
              },
              "value": "Male or female",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Sex: * Male or female",
              "mapping_rationale": "Explicit statement of eligible sexes",
              "id": "1985a15e-2f1e-4c4d-b97d-a3965ab634e0"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "PerformanceStatus",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "performancestatus",
                "display": "PerformanceStatus"
              },
              "value": "80-100%",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Performance status: * Karnofsky 80-100%",
              "mapping_rationale": "Direct statement of Karnofsky performance status requirement",
              "id": "ce6a5740-41cd-4f75-a76e-5ec8855a9ec4"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Locally advanced breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "patients with locally advanced breast cancer who will undergo chemotherapy",
              "mapping_rationale": "Direct, unambiguous statement of cancer diagnosis",
              "id": "b2665049-9667-4b48-a474-17bcebce321e"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Chemotherapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "patients with locally advanced breast cancer who will undergo chemotherapy",
              "mapping_rationale": "Direct statement of chemotherapy treatment",
              "id": "c0c00bdf-044c-4249-91db-221b15ea81ca"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Radiation therapy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "the patient may be offered radiation therapy",
              "mapping_rationale": "Direct statement of radiation therapy treatment option",
              "id": "946a9362-1350-4022-beaa-0f4674659b1f"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerTreatment",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancertreatment",
                "display": "CancerTreatment"
              },
              "value": "Surgical resection",
              "mapping_confidence": 1.0,
              "source_text_fragment": "the patient is evaluated for surgical resection of the tumor",
              "mapping_rationale": "Direct statement of surgical treatment option",
              "id": "4a856a87-0533-46b0-8c3b-bc5de315b596"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerImaging",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerimaging",
                "display": "CancerImaging"
              },
              "value": "PET scan",
              "mapping_confidence": 1.0,
              "source_text_fragment": "The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy",
              "mapping_rationale": "Direct statement of PET scan imaging procedure",
              "id": "0be71d21-47bc-48fd-bab9-af13dc442c2c"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerImaging",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerimaging",
                "display": "CancerImaging"
              },
              "value": "FDG PET scan",
              "mapping_confidence": 1.0,
              "source_text_fragment": "followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion",
              "mapping_rationale": "Direct statement of FDG PET scan imaging procedure",
              "id": "caa447ce-d38c-402f-883a-f4ef4082a16d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerImaging",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerimaging",
                "display": "CancerImaging"
              },
              "value": "IUdR PET scan",
              "mapping_confidence": 1.0,
              "source_text_fragment": "There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion",
              "mapping_rationale": "Direct statement of IUdR PET scan imaging procedure",
              "id": "aebed8c8-e662-48b2-8deb-c371e35b7b83"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerImaging",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerimaging",
                "display": "CancerImaging"
              },
              "value": "CT scans",
              "mapping_confidence": 1.0,
              "source_text_fragment": "which will include CT scans as well as bone scans",
              "mapping_rationale": "Direct statement of CT scan imaging procedure",
              "id": "c3d90a83-af50-4fcc-8e37-e97bd95cbcd1"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerImaging",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerimaging",
                "display": "CancerImaging"
              },
              "value": "Bone scans",
              "mapping_confidence": 1.0,
              "source_text_fragment": "which will include CT scans as well as bone scans",
              "mapping_rationale": "Direct statement of bone scan imaging procedure",
              "id": "44cfe0ac-8057-4c88-aa7b-bb29f6bfef8f"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Locally advanced breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "PET Scans in Patients With Locally Advanced Breast Cancer",
              "mapping_rationale": "Direct statement of cancer diagnosis in title",
              "id": "a4f4af60-5405-45e4-846e-f2bd1917d77a"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Advanced breast cancer",
              "mapping_confidence": 1.0,
              "source_text_fragment": "in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose",
              "mapping_rationale": "Explicit mention of advanced breast cancer in official title",
              "id": "c112de06-3cdf-440f-ad19-17531346cd79"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 17,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 848,
              "completion_tokens": 309,
              "total_tokens": 1157
            },
            "aggregate_token_usage": {
              "prompt_tokens": 4711,
              "completion_tokens": 2368,
              "total_tokens": 7079,
              "model_name": "deepseek-coder",
              "provider_name": "deepseek"
            }
          }
        },
        {
          "trial_id": "NCT00616135",
          "processing_time": 153.70884609222412,
          "mcode_mappings": [
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast Neoplasms",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Breast Neoplasms",
              "mapping_rationale": "Direct statement of breast cancer diagnosis",
              "id": "26f5f459-1ff0-4c08-a868-0b6e0b25eeaa"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Carcinoma, Ductal, Breast",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Carcinoma, Ductal, Breast",
              "mapping_rationale": "Direct statement of ductal carcinoma histology",
              "id": "ae25dbb6-b796-420f-809e-0157f1340405"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast carcinoma",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Females with a history of T2N0M0 breast carcinoma (tumor \u22643 cm in largest dimension)",
              "mapping_rationale": "Direct statement of breast carcinoma diagnosis",
              "id": "bea6b708-6b1c-4e38-83dd-427bafbe6261"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TNMStage",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tnmstage",
                "display": "TNMStage"
              },
              "value": "T2N0M0",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Females with a history of T2N0M0 breast carcinoma (tumor \u22643 cm in largest dimension)",
              "mapping_rationale": "Explicit TNM staging provided",
              "id": "839676c6-bfab-4c67-be79-c7e767bf30d8"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "TumorSize",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "tumorsize",
                "display": "TumorSize"
              },
              "value": "\u22643 cm",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Females with a history of T2N0M0 breast carcinoma (tumor \u22643 cm in largest dimension)",
              "mapping_rationale": "Explicit tumor size measurement",
              "id": "7734bce4-1bff-46c7-ba32-904bbcead969"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "Segmental mastectomy or quadrantectomy (lumpectomy)",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)",
              "mapping_rationale": "Direct statement of surgical procedure performed",
              "id": "03ee5489-1ac8-4a5c-a9e4-1126d237ab27"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Sex",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "sex",
                "display": "Sex"
              },
              "value": "Female",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Females with a history of T2N0M0 breast carcinoma",
              "mapping_rationale": "Explicit statement of female sex",
              "id": "00163800-1bd2-4a98-97df-9215c0f59816"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "Age",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "age",
                "display": "Age"
              },
              "value": "18-75 years",
              "mapping_confidence": 1.0,
              "source_text_fragment": "minimumAge: 18 Years maximumAge: 75 Years",
              "mapping_rationale": "Explicit age range criteria",
              "id": "c28f9a16-6fa1-40c6-85e5-ec4395d599b1"
            },
            {
              "resourceType": "MedicationStatement",
              "Mcode_element": "CancerRelatedMedication",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedmedication",
                "display": "CancerRelatedMedication"
              },
              "value": "Anti-estrogen adjuvant therapy",
              "mapping_confidence": 0.9,
              "source_text_fragment": "patients on anti-estrogen adjuvant therapy are NOT excluded",
              "mapping_rationale": "Direct mention of anti-estrogen therapy medication",
              "id": "d53145e4-1091-4ea0-b3ec-6e046e340521"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Absence of recurrence",
              "mapping_confidence": 0.8,
              "source_text_fragment": "Last treatment for breast cancer \u2265 12 months prior to enrollment with absence of recurrence",
              "mapping_rationale": "Explicit statement about cancer recurrence status",
              "id": "2a2998f4-8793-466d-bcda-d92a9ed754c4"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast cancer",
              "mapping_confidence": 0.9,
              "source_text_fragment": "breast deformities post segmental mastectomy or quadrantectomy (lumpectomy)",
              "mapping_rationale": "Explicit reference to breast cancer treatment procedures (mastectomy/lumpectomy) indicating cancer diagnosis",
              "id": "99fcf81d-3eb9-4d32-8481-41ef1b61d1e6"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "Segmental mastectomy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "post segmental mastectomy or quadrantectomy (lumpectomy)",
              "mapping_rationale": "Direct mention of segmental mastectomy as cancer treatment procedure",
              "id": "28993e2d-7545-4e93-b586-92eb62016129"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "Lumpectomy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "quadrantectomy (lumpectomy)",
              "mapping_rationale": "Explicit statement of lumpectomy as cancer treatment procedure",
              "id": "75a4c1f1-5ba3-4e3d-be8e-950599937577"
            },
            {
              "resourceType": "Condition",
              "Mcode_element": "CancerCondition",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancercondition",
                "display": "CancerCondition"
              },
              "value": "Breast cancer",
              "mapping_confidence": 0.9,
              "source_text_fragment": "BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy)",
              "mapping_rationale": "Lumpectomy is explicitly stated as a surgical procedure for breast cancer treatment",
              "id": "87714532-532e-44dd-96f7-cd99db89634d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "Lumpectomy",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Segmental Breast ResecTion (Lumpectomy)",
              "mapping_rationale": "Lumpectomy is explicitly mentioned as the surgical procedure performed",
              "id": "816d238c-888c-424e-80b6-8aa2a275db7d"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "CancerRelatedSurgicalProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "cancerrelatedsurgicalprocedure",
                "display": "CancerRelatedSurgicalProcedure"
              },
              "value": "Autologous fat transplant",
              "mapping_confidence": 1.0,
              "source_text_fragment": "Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities",
              "mapping_rationale": "Autologous fat transplantation is explicitly stated as the reconstructive procedure",
              "id": "9d85bfd2-6d3d-4344-9e22-a7e52a11d047"
            },
            {
              "resourceType": "Observation",
              "Mcode_element": "RadiationProcedure",
              "code": {
                "system": "http://hl7.org/fhir/us/mCODE",
                "code": "radiationprocedure",
                "display": "RadiationProcedure"
              },
              "value": "Radiation therapy",
              "mapping_confidence": 0.8,
              "source_text_fragment": "With Or Without Radiation ThErapy",
              "mapping_rationale": "Radiation therapy is explicitly mentioned as a potential treatment modality",
              "id": "7132a220-ef79-4ec5-b56f-624cfc8555ff"
            }
          ],
          "source_references": [],
          "validation_results": {
            "valid": true,
            "errors": [],
            "warnings": [],
            "compliance_score": 1.0
          },
          "metadata": {
            "pipeline_version": "Mcode_pipeline_v1",
            "engine_type": "LLM",
            "entities_count": 0,
            "mapped_count": 17,
            "compliance_score": 1.0,
            "token_usage": {
              "prompt_tokens": 855,
              "completion_tokens": 575,
              "total_tokens": 1430
            },
            "aggregate_token_usage": {
              "prompt_tokens": 4461,
              "completion_tokens": 2431,
              "total_tokens": 6892,
              "model_name": "deepseek-coder",
              "provider_name": "deepseek"
            }
          }
        }
      ],
      "quality_analysis": {
        "total_mappings": 118,
        "avg_confidence": 0.9822033898305085,
        "high_confidence_count": 118,
        "with_source_text": 117,
        "source_text_ratio": 0.9915254237288136,
        "confidence_distribution": {
          "high (0.8-1.0)": 118,
          "medium (0.5-0.8)": 0,
          "low (0.0-0.5)": 0
        },
        "quality_score": 0.9894915254237289
      }
    }
  },
  "validation_analysis": {
    "improvements_detected": [
      "Source text quality improved: 0.99 vs 0.91",
      "Average confidence improved: 0.98 vs 0.90",
      "Reduced over-mapping: 118 vs 214 mappings (quality over quantity)",
      "Overall quality score improved: 0.989 vs 0.904"
    ],
    "concerns_identified": [],
    "overall_assessment": "significant_improvement"
  },
  "recommendations": [
    "\u2705 Deploy evidence-based prompt for production use",
    "\u2705 Update default prompt configuration",
    "\u2705 Consider this as new quality benchmark"
  ]
}